Rolf Lewensohn | Karolinska Institutet

Om mig
Publikationer
Forskningsbidrag
CV
Populärvetenskap och samverkan

Om mig

Professor i onkologi vid Karolinska Institutet, överläkare vid Karolinska Sjukhusets onkologiska klinik.

- Född 1949, leder en forskargrupp med ca 20 medarbetare på institutionen för onkologi-patologi.
- Programdirektör för Socialstyrelsens Kunskapscentrum för strålningsmedicin vid katastrofer (KcRN
SREMC) som är en beredskapsfunktion vid Centrum för strålningsmedicin.
- Ledamot i flera forskningsnämnder, t ex för Konung Gustaf V:s Jubileumsfond.
- Över 110 vetenskapliga publikationer om cancer.

Forskningsbeskrivning

Rolf Lewensohns vetenskapliga bakgrund innefattar DNA-reparation och apoptos-signalering med sikte på cancer och cancerbehandling. Han har varit ledande i uppbyggnaden av ett kliniskt vård- och forskningsprogram för lungcancer i Stockholmsregionen och har byggt upp ett kliniskt forskningsprogram för utveckling av ny cancerbehandling. Han är drivande i att etablera ”personalized cancer medicine” vid Karolinska Institutet.

Lewensohn och hans forskningsgrupp studerar hur kemoterapi och strålbehandling orsakar skador i tumörcellernas DNA och nedströms signalering. Han har tillsammans med sina medarbetare funnit att tumörer som har hög förmåga att reparera DNA-skador visar resistens mot strål- respektive kemoterapi av solida tumörer. Lewensohns forskargrupp arbetar med att identifiera proteiner som är ansvariga för behandlingsresistens samt även med läkemedel som kan användas för att kringgå sådan resistens.

För ytterligare, mer detaljerad information, se den engelska presentationssidan.

Artiklar

Journal article: TRANSLATIONAL LUNG CANCER RESEARCH. 2024;0(0):0
Treatment of metastatic ALK-positive non-small cell lung cancer: real-world outcomes in a single center study
Kamali C; Tsakonas G; Hydbring P; Jatta K; Berglund A; Viktorsson K; Lewensohn R; De Petris L; Ekman S
Journal article: CLINICAL AND TRANSLATIONAL SCIENCE. 2024;17(8):e13909
Exploring the discrepancies between clinical trials and real-world data: A small-cell lung cancer study
Marzano L; Darwich AS; Dan A; Tendler S; Lewensohn R; De Petris L; Raghothama J; Meijer S
Journal article: ACS SENSORS. 2024;9(6):2935-2945
Design and Optimization of a Silicon-Based Electrokinetic Microchip for Sensitive Detection of Small Extracellular Vesicles
Gevari MT; Sahu SS; Stridfeldt F; Haag P; De Petris L; Viktorsson K; Lewensohn R; Gori A; Cretich M; Dev A
Journal article: ESMO OPEN. 2024;9:102781
208P The discrepancies between real-world evidence and clinical trials: A study investigating stage IV SCLC
Marzano L; Dan A; Tendler S; Darwich AS; de Petris L; Lewensohn R; Raghothama J; Meijer S
Article: ACTA ONCOLOGICA. 2023;62(12):1921-1930
Radiotherapy with or without immunotherapy in metastatic melanoma: efficacy and Tolerability
Backlund E; Grozman V; Brage SE; Lewensohn R; Lindberg K; Helgadottir H
Article: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2023;117(5):1222-1231
Expanded HILUS Trial: A Pooled Analysis of Risk Factors for Toxicity From Stereotactic Body Radiation Therapy of Central and Ultracentral Lung Tumors
Lindberg S; Grozman V; Karlsson K; Onjukka E; Lindback E; Al Jirf K; Lax I; Wersall P; Persson GF; Josipovic M; Khalil AA; Moller DS; Hoffmann L; Knap MM; Nyman J; Drugge N; Bergstrom P; Olofsson J; Rogg LV; Hagen RK; Froland A-S; Ramberg C; Kristiansen C; Jeppesen SS; Nielsen TB; Loden B; Rosenbrand H-O; Engelholm S; Haraldsson A; Billiet C; Lewensohn R; Lindberg K
Journal article: JOURNAL OF THORACIC ONCOLOGY. 2023;18(11):s353
P2.10-04 Real-World Outcome of Metastatic ALK-Positive Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors
Kamali C; De Petris L; Jatta K; Viktorsson K; Lewensohn R; Ekman S; Hydbring P
Journal article: JOURNAL OF THORACIC ONCOLOGY. 2023;18(11):s697
EP13.03-14 A Comparative Analysis between Real-World Data and Clinical Trials to Evaluate Differences in Outcomes for SCLC Patients
Marzano L; Dan A; Tendler S; Darwich AS; Raghothama J; De Petris L; Lewensohn R; Meijer S
Journal article: JOURNAL OF GLOBAL ONCOLOGY. 2023;9(Supplement_1):113
Explainable machine learning to inform real-world evidence: A case study on small cell lung cancer survival analysis.
Marzano L; Darwich AS; Dan A; Tendler S; Raghotama J; Lewensohn R; De Petris L; Meijer S
Article: LUNG CANCER. 2023;182:107292
Cerebrospinal fluid as a liquid biopsy for molecular characterization of brain metastasis in patients with non-small cell lung cancer
Tsakonas G; Tadigotla V; Chakrabortty SK; Stragliotto G; Chan D; Lewensohn R; Yu W; Skog JK; Hydbring P; Ekman S
Article: CYTOPATHOLOGY. 2023;34(4):286-294
Multiplex protein analysis and ensemble machine learning methods of fine needle aspirates from prostate cancer patients reveal potential diagnostic signatures associated with tumour grade
Robeck P; Franzen B; Cantera-Ahlman R; Dragomir A; Auer G; Jorulf H; Jacobsson SP; Viktorsson K; Lewensohn R; Haggman M; Ladjevardi S
Article: TALANTA. 2023;259:124553
Analyses of single extracellular vesicles from non-small lung cancer cells to reveal effects of epidermal growth factor receptor inhibitor treatments
Stridfeldt F; Cavallaro S; Haag P; Lewensohn R; Linnros J; Viktorsson K; Dev A
Article: CLINICAL AND TRANSLATIONAL SCIENCE. 2023;16(6):955-965
Brain exposure of osimertinib in patients with epidermal growth factor receptor mutation non-small cell lung cancer and brain metastases: A positron emission tomography and magnetic resonance imaging study
Ekman S; Cselenyi Z; Varrone A; Jucaite A; Martin H; Schou M; Johnstrom P; Laus G; Lewensohn R; Brown AP; van der Aart J; Vishwanathan K; Farde L
Article: STUDIES IN HEALTH TECHNOLOGY AND INFORMATICS. 2023;302:18-22
Application of Process Mining for Modelling Small Cell Lung Cancer Prognosis.
Marzano L; Meijer S; Dan A; Tendler S; De Petris L; Lewensohn R; Raghothama J; Darwich AS
Article: BIOSENSORS AND BIOELECTRONICS. 2023;227:115142
Multi-marker profiling of extracellular vesicles using streaming current and sequential electrostatic labeling
Sahu SS; Gevari MT; Nagy A; Gestin M; Haag P; Lewensohn R; Viktorsson K; Karlstrom AE; Dev A
Journal article: RADIOTHERAPY AND ONCOLOGY. 2023;181:109492
18F-FDG-PET guided vs whole tumour radiotherapy dose escalation in patients with locally advanced non-small cell lung cancer (PET-Boost): Results from a randomised clinical trial
Cooke SA; de Ruysscher D; Reymen B; Lambrecht M; Persson GF; Faivre-Finn C; Dieleman EMT; Lewensohn R; Diessen JNAV; Sikorska K; Lalezari F; Vogel W; van Elmpt W; Damen EMF; Sonke J-J; Belderbos JSA
Article: CELL DEATH DISCOVERY. 2022;8(1):464
Proof-of-principle studies on a strategy to enhance nucleotide imbalance specifically in cancer cells
Alkasalias T; Zhang J; Madapura H; Dalarun B; Reina OB; Lewensohn R; Viktorsson K; Salihi A; Darekar S; Lain S
Article: JOURNAL OF EXTRACELLULAR VESICLES. 2022;11(11):e12277
Characterizing single extracellular vesicles by droplet barcode sequencing for protein analysis
Banijamali M; Hojer P; Nagy A; Haag P; Paz Gomero E; Stiller C; Kaminskyy VO; Ekman S; Lewensohn R; Karlstrom AE; Viktorsson K; Ahmadian A
Article: MOLECULAR ONCOLOGY. 2022;16(20):3620-3641
Profiling of extracellular vesicles of metastatic urothelial cancer patients to discover protein signatures related to treatment outcome
Viktorsson K; Haag P; Shah C-H; Franzen B; Arapi V; Holmsten K; Sandstrom P; Lewensohn R; Ullen A
Article: TRANSLATIONAL LUNG CANCER RESEARCH. 2022;11(10):2064-2078
Plasma RNA profiling unveils transcriptional signatures associated with resistance to osimertinib in EGFR T790M positive non-small cell lung cancer patients
Alexeyenko A; Brustugun OT; Eide IJZ; Gencheva R; Kosibaty Z; Lai Y; de Petris L; Tsakonas G; Grundberg O; Franzen B; Viktorsson K; Lewensohn R; Hydbring P; Ekman S
Article: CLINICAL AND TRANSLATIONAL SCIENCE. 2022;15(10):2437-2447
A novel analytical framework for risk stratification of real-world data using machine learning: A small cell lung cancer study
Marzano L; Darwich AS; Tendler S; Dan A; Lewensohn R; De Petris L; Raghothama J; Meijer S
Journal article: JOURNAL OF THORACIC ONCOLOGY. 2022;17(9):s156
P2.13-03 Plasma Profiling Unveils Transcriptional Signatures Associated with Resistance to Osimertinib in Non-Small Cell Lung Cancer
Alexeyenko A; Brustugun OT; Eide IJZ; Gencheva R; Kosibaty Z; Lai Y; de Petris L; Tsakonas G; Grundberg O; Franzen B; Viktorsson K; Lewensohn R; Hydbring P; Ekman S
Journal article: JOURNAL OF THORACIC ONCOLOGY. 2022;17(9):s574
EP16.02-008 Cerebrospinal Fluid as a Liquid Biopsy for Molecular Characterization of Brain Metastases in Patients With Non-small Cell Lung Cancer
Tsakonas G; Tadigotla V; Chakrabortty S; Stragliotto G; Chan D; Lewensohn R; Yu W; Skog JK; Hydbring P; Ekman S
Article: CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY. 2022;36:91-98
Predicting the benefit of stereotactic body radiotherapy of colorectal cancer metastases
Lindberg S; Onjukka E; Wersall P; Staff C; Lewensohn R; Masucci G; Lindberg K
Article: CELL DEATH DISCOVERY. 2022;8(1):284
Caspase-2 is a mediator of apoptotic signaling in response to gemtuzumab ozogamicin in acute myeloid leukemia
Haag P; Olsson M; Forsberg J; Lindberg ML; Stenerlow B; Zong D; Kanter L; Lewensohn R; Viktorsson K; Zhivotovsky B; Stenke L
Article: TRANSLATIONAL LUNG CANCER RESEARCH. 2022;11(5):722-734
Elevated expression of miR-494-3p is associated with resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer
Kazmierczak D; Eide IJZ; Gencheva R; Lai Y; Lewensohn R; Tsakonas G; Grundberg O; de Petris L; McGowan M; Brustugun OT; Ekman S; Hydbring P
Article: MARINE DRUGS. 2022;20(4):265
Cytotoxic Alkylynols of the Sponge Cribrochalina vasculum: Structure, Synthetic Analogs and SAR Studies
Kovalerchik D; Zovko A; Haag P; Sierakowiak A; Viktorsson K; Lewensohn R; Ilan M; Carmeli S
Article: BASIC AND CLINICAL PHARMACOLOGY AND TOXICOLOGY. 2022;130(4):513-521
The association of four genetic variants with myelosuppression in gemcitabine-treated Japanese is not evident in gemcitabine/carboplatin-treated Swedes
Bjorn N; Jakobsen I; Udagawa C; Branden E; Koyi H; Lewensohn R; De Petris L; Zembutsu H; Green H
Article: BIOSENSORS AND BIOELECTRONICS. 2021;193:113568
Multiplexed electrokinetic sensor for detection and therapy monitoring of extracellular vesicles from liquid biopsies of non-small-cell lung cancer patients
Cavallaro S; Haag P; Sahu SS; Berisha L; Kaminskyy VO; Ekman S; Lewensohn R; Linnros J; Viktorsson K; Dev A
Article: MOLECULAR ONCOLOGY. 2021;15(11):2941-2957
Multiplex immune protein profiling of fine-needle aspirates from patients with non-small-cell lung cancer reveals signatures associated with PD-L1 expression and tumor stage
Franzen B; Viktorsson K; Kamali C; Darai-Ramqvist E; Grozman V; Arapi V; Haag P; Kaminskyy VO; Hydbring P; Kanter L; Nyren S; Ekman S; De Petris L; Lewensohn R
Journal article: JOURNAL OF THORACIC ONCOLOGY. 2021;16(10):s974
FP16.04 A Nationwide Population-Based Mapping of Mutations and Gene Fusions in Lung Cancer Among Never-Smokers
Salomonsson A; Jönsson M; Behndig A; Bergman B; Botling J; Brandén E; Koyi H; Brunnström H; De Petris L; Helenius G; Hussein A; Johansson M; Kentson M; Lamberg K; Lewensohn R; Mager U; Monsef N; Ortiz-Villalon C; Patthey A; Sundh J; Vikström A; Wagenius G; Staaf J; Planck M
Article: ACS APPLIED MATERIALS & INTERFACES. 2021;13(36):42513-42521
Exploiting Electrostatic Interaction for Highly Sensitive Detection of Tumor-Derived Extracellular Vesicles by an Electrokinetic Sensor
Sahu SS; Cavallaro S; Haag P; Nagy A; Karlstrom AE; Lewensohn R; Viktorsson K; Linnros J; Dev A
Article: CANCERS. 2021;13(16):4164
Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy
Madonna G; Masucci GV; Capone M; Mallardo D; Grimaldi AM; Simeone E; Vanella V; Festino L; Palla M; Scarpato L; Tuffanelli M; D'angelo G; Villabona L; Krakowski I; Eriksson H; Simao F; Lewensohn R; Ascierto PA
Article: JOURNAL OF THORACIC ONCOLOGY. 2021;16(7):1200-1210
The HILUS-Trial-a Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Stereotactic Body Radiotherapy
Lindberg K; Grozman V; Karlsson K; Lindberg S; Lax I; Wersall P; Persson GF; Josipovic M; Khalil AA; Moeller DS; Nyman J; Drugge N; Bergstrom P; Olofsson J; Rogg LV; Ramberg C; Kristiansen C; Jeppesen SS; Nielsen TB; Loden B; Rosenbrand H-O; Engelholm S; Haraldsson A; Billiet C; Lewensohn R
Article: NANOSCALE ADVANCES. 2021;3(11):3053-3063
Comparison and optimization of nanoscale extracellular vesicle imaging by scanning electron microscopy for accurate size-based profiling and morphological analysis
Cavallaro S; Haag P; Viktorsson K; Krozer A; Fogel K; Lewensohn R; Linnros J; Dev A
Article: ACTA ONCOLOGICA. 2021;60(3):305-311
Extending hypofractionated stereotactic body radiotherapy to tumours larger than 70cc-effects and side effects
Grozman V; Onjukka E; Wersall P; Lax I; Tsakonas G; Nyren S; Lewensohn R; Lindberg K
Journal article: JOURNAL OF THORACIC ONCOLOGY. 2021;16(3):s620
P76.72 A PET and MRI Study Exploring Osimertinib Brain Exposure and Efficacy in EGFRm NSCLC CNS Metastases
Ekman S; Cselényi Z; Varrone A; Jucaite A; Martin H; Schou M; Johnström P; Laus G; Lewensohn R; Brown A; Van Der Aart J; Vishwanathan K; Farde L
Article: CANCERS. 2021;13(5):1010
EPHA2 Interacts with DNA-PK_cs in Cell Nucleus and Controls Ionizing Radiation Responses in Non-Small Cell Lung Cancer Cells
Kaminskyy VO; Haag P; Novak M; Vegvari A; Arapi V; Lewensohn R; Viktorsson K
Article: CANCERS. 2021;13(4):922
Detection of Tumor-Associated Membrane Receptors on Extracellular Vesicles from Non-Small Cell Lung Cancer Patients via Immuno-PCR
Stiller C; Viktorsson K; Paz Gomero E; Haag P; Arapi V; Kaminskyy VO; Kamali C; De Petris L; Ekman S; Lewensohn R; Karlstrom AE
Journal article: RADIOTHERAPY AND ONCOLOGY. 2020;152:s345-s346
OC-0609: The PET-boost trial: isotoxic homogeneous or FDG-directed dose escalation in stage II-III NSCLC
Cooke S; De Ruysscher D; Reymen B; Lambrecht M; Persson GF; Faivre-Finn C; Dieleman E; Lewensohn R; Van Diessen J; Sikorska K; Lalezari F; Sonke J; Belderbos J
Article: LUNG CANCER. 2020;147:106-114
Genetic association of gemcitabine/carboplatin-induced leukopenia and neutropenia in non-small cell lung cancer patients using whole-exome sequencing
Svedberg A; Bjorn N; Sigurgeirsson B; Pradhananga S; Branden E; Koyi H; Lewensohn R; De Petris L; Apellaniz-Ruiz M; Rodriguez-Antona C; Lundeberg J; Green H
Article: NPJ SYSTEMS BIOLOGY AND APPLICATIONS. 2020;6(1):25
Whole-genome sequencing and gene network modules predict gemcitabine/carboplatin-induced myelosuppression in non-small cell lung cancer patients
Bjorn N; Badam TVS; Spalinskas R; Branden E; Koyi H; Lewensohn R; De Petris L; Lubovac-Pilav Z; Sahlen P; Lundeberg J; Gustafsson M; Green H
Article: CANCERS. 2020;12(7):E1804-1804
ALK-Brain Prognostic Index-Preliminary Study of a Prognostic Tool for Patients with ALK-Rearranged, Non-small Cell Lung Cancer and Brain Metastases
Tsakonas G; Kamali C; De Petris L; Friesland S; Lewensohn R; Ekman S
Article: EUROPEAN JOURNAL OF CANCER. 2020;132:24-34
An immune gene expression signature distinguishes central nervous system metastases from primary tumours in non-small-cell lung cancer
Tsakonas G; Lewensohn R; Botling J; Ortiz-Villalon C; Micke P; Friesland S; Nord H; Lindskog M; Sandelin M; Hydbring P; Ekman S
Article: ACTA ONCOLOGICA. 2020;59(4):388-394
Treatment patterns and survival outcomes for small-cell lung cancer patients - a Swedish single center cohort study
Tendler S; Zhan Y; Pettersson A; Lewensohn R; Viktorsson K; Fang F; De Petris L
Article: PHARMACOGENOMICS JOURNAL. 2020;20(2):179-191
Genes and variants in hematopoiesis-related pathways are associated with gemcitabine/carboplatin-induced thrombocytopenia
Bjorn N; Sigurgeirsson B; Svedberg A; Pradhananga S; Branden E; Koyi H; Lewensohn R; de Petris L; Apellaniz-Ruiz M; Rodriguez-Antona C; Lundeberg J; Green H
Article: PLOS ONE. 2020;15(10):e0240973
The prognostic implications of Notch1, Hes1, Ascl1, and DLL3 protein expression in SCLC patients receiving platinum-based chemotherapy
Tendler S; Kanter L; Lewensohn R; Ortiz-Villalon C; Viktorsson K; De Petris L
Article: LUNG CANCER. 2020;139:111-117
Educational level, management and outcomes in small-cell lung cancer (SCLC): A population-based cohort study
Tendler S; Holmqvist M; Wagenius G; Lewensohn R; Lambe M; De Petris L
Article: ACTA ONCOLOGICA. 2019;58(8):1178-1186
Radiation-induced brachial plexus toxicity after SBRT of apically located lung lesions
Lindberg K; Grozman V; Lindberg S; Onjukka E; Lax I; Lewensohn R; Wersall P
Article: ACS SENSORS. 2019;4(5):1399-1408
Label-Free Surface Protein Profiling of Extracellular Vesicles by an Electrokinetic Sensor
Cavallaro S; Horak J; Haag P; Gupta D; Stiller C; Sahu SS; Gorgens A; Gatty HK; Viktorsson K; El Andaloussi S; Lewensohn R; Karlstrom AE; Linnros J; Dev A
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2019;511(2):260-265
miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC
Lai Y; Kacal M; Kanony M; Stukan I; Jatta K; Kis L; Norberg E; Vakifahmetoglu-Norberg H; Lewensohn R; Hydbring P; Ekman S
Article: MOLECULAR ONCOLOGY. 2019;13(2):376-391
Protein profiling of fine-needle aspirates reveals subtype-associated immune signatures and involvement of chemokines in breast cancer
Franzen B; Alexeyenko A; Kamali-Moghaddam M; Hatschek T; Kanter L; Ramqvist T; Kierkegaard J; Masucci G; Auer G; Landegren U; Lewensohn R
Article: LUNG CANCER. 2018;124:45-52
Exosomal RNA-profiling of pleural effusions identifies adenocarcinoma patients through elevated miR-200 and LCN2 expression
Hydbring P; De Petris L; Zhang Y; Branden E; Koyi H; Novak M; Kanter L; Haag P; Hurley J; Tadigotla V; Zhu B; Skog J; Viktorsson K; Ekman S; Lewensohn R
Article: MOLECULAR ONCOLOGY. 2018;12(9):1415-1428
A fine-needle aspiration-based protein signature discriminates benign from malignant breast lesions
Franzen B; Kamali-Moghaddam M; Alexeyenko A; Hatschek T; Becker S; Wik L; Kierkegaard J; Eriksson A; Muppani NR; Auer G; Landegren U; Lewensohn R
Article: LUNG CANCER. 2018;120:75-81
Validation of the 8th TNM classification for small-cell lung cancer in a retrospective material from Sweden
Tendler S; Grozman V; Lewensohn R; Tsakonas G; Viktorsson K; De Petris L
Article: ACTA ONCOLOGICA. 2018;57(2):231-238
Prognostic factors affecting survival after whole brain radiotherapy in patients with brain metastasized lung cancer
Tsakonas G; Hellman F; Gubanski M; Friesland S; Tendler S; Lewensohn R; Ekman S; de Petris L
Article: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2018;100(1):174-187
Analysis of Chromatin Opening in Heterochromatic Non-Small Cell Lung Cancer Tumor-Initiating Cells in Relation to DNA-Damaging Antitumor Treatment
Eriksson M; Haag P; Brzozowska B; Lipka M; Lisowska H; Lewensohn R; Wojcik A; Viktorsson K; Lundholm L
Article: RADIATION ONCOLOGY. 2017;12(1):206
Tumor treating fields (TTFields) delay DNA damage repair following radiation treatment of glioma cells
Giladi M; Munster M; Schneiderman RS; Voloshin T; Porat Y; Blat R; Zielinska-Chomej K; Haag P; Bomzon Z; Kirson ED; Weinberg U; Viktorsson K; Lewensohn R; Palti Y
Journal article: JOURNAL OF THORACIC ONCOLOGY. 2017;12(11):s1922-s1923
P1.01-074 Exosomal RNA-Profiling of Lung Pleural Effusions Identifies Adenocarcinoma Patients through Elevated miR-200 Expression
Hydbring P; De Petris L; Branden E; Koyi H; Novak M; Kanter L; Hååg P; Hurley J; Tadigotla V; Skog J; Viktorsson K; Ekman S; Lewensohn R
Journal article: JOURNAL OF THORACIC ONCOLOGY. 2017;12(11):s2114
P2.02-042 Clinical Significance of the Tumor Expression of PD-L1 Using Four Immunohistochemistry Assays in Non-Small Cell Lung Cancer. Multicentre Study
–Villalón CO; Yoshikawa A; Kis L; Montero A; Roden A; Pham HHN; Fernandez C; Fukuoka J; Lewensohn R; De Petris L
Journal article: ONCOGENE. 2017;36(33):4818
Mitochondrial dysfunction is an essential step for killing of non-small cell lung carcinomas resistant to conventional treatment.
Joseph B; Marchetti P; Formstecher P; Kroemer G; Lewensohn R; Zhivotovsky B
Article: RADIOTHERAPY AND ONCOLOGY. 2016;121(1):1-8
SPACE - A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC
Nyman J; Hallqvist A; Lund J-A; Brustugun O-T; Bergman B; Bergstrom P; Friesland S; Lewensohn R; Holmberg E; Lax I
Article: ONCOTARGET. 2016;7(37):60332-60347
Ephrin B3 interacts with multiple EphA receptors and drives migration and invasion in non-small cell lung cancer
Efazat G; Novak M; Kaminskyy VO; De Petris L; Kanter L; Juntti T; Bergman P; Zhivotovsky B; Lewensohn R; Haag P; Viktorsson K
Article: ONCOTARGET. 2016;7(37):59322-59335
Preclinical activity of melflufen (J1) in ovarian cancer
Carlier C; Strese S; Viktorsson K; Velander E; Nygren P; Uustalu M; Juntti T; Lewensohn R; Larsson R; Spira J; De Vlieghere E; Ceelen WP; Gullbo J
Article: ONCOTARGET. 2016;7(31):50258-50276
Compounds from the marine sponge Cribrochalina vasculum offer a way to target IGF-1R mediated signaling in tumor cells
Zovko A; Novak M; Haag P; Kovalerchick D; Holmlund T; Farnegardh K; Ilan M; Carmeli S; Lewensohn R; Viktorsson K
Journal article: CANCER RESEARCH. 2016;76(14_Supplement):3355
Abstract 3355: Opening up heterochromatin by histone deacetylase inhibition improves response to DNA damage in lung cancer tumor initiating cells
Lundholm L; Hååg P; Eriksson M; Brzozowska B; Lewensohn R; Wojcik A; Viktorsson K
Article: MOLECULAR ONCOLOGY. 2016;10(5):719-734
Melphalan-flufenamide is cytotoxic and potentiates treatment with chemotherapy and the Src inhibitor dasatinib in urothelial carcinoma
Viktorsson K; Shah C-H; Juntti T; Haag P; Zielinska-Chomej K; Sierakowiak A; Holmsten K; Tu J; Spira J; Kanter L; Lewensohn R; Ullen A
Article: CLINICAL CANCER RESEARCH. 2016;22(2):366-373
Using Whole-Exome Sequencing to Identify Genetic Markers for Carboplatin and Gemcitabine-Induced Toxicities
Green H; Hasmats J; Kupershmidt I; Edsgard D; de Petris L; Lewensohn R; Blackhall F; Vikingsson S; Besse B; Lindgren A; Branden E; Koyi H; Peterson C; Lundeberg J
Article: INVESTIGATIONAL NEW DRUGS. 2015;33(6):1232-1241
First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies
Berglund A; Ullen A; Lisyanskaya A; Orlov S; Hagberg H; Tholander B; Lewensohn R; Nygren P; Spira J; Harmenberg J; Jerling M; Alvfors C; Ringbom M; Nordstrom E; Soderlind K; Gullbo J
Article: ACTA ONCOLOGICA. 2015;54(8):1096-1104
Long-term results of a prospective phase II trial of medically inoperable stage I NSCLC treated with SBRT - the Nordic experience
Lindberg K; Nyman J; Kallskog VR; Hoyer M; Lund JA; Lax I; Wersall P; Karlsson K; Friesland S; Lewensohn R
Article: BMC CANCER. 2015;15:628
DKK1 is a potential novel mediator of cisplatin-refractoriness in non-small cell lung cancer cell lines
Salim H; Zong D; Haag P; Novak M; Mork B; Lewensohn R; Lundholm L; Viktorsson K
Article: JOURNAL OF MOLECULAR DIAGNOSTICS. 2015;17(4):352-359
Toward Rare Blood Cell Preservation for RNA Sequencing
Vickovic S; Ahmadian A; Lewensohn R; Lundeberg J
Journal article: RADIOTHERAPY AND ONCOLOGY. 2015;115:s324-s325
PO-0665: Radiation induced brachial plexus toxicity after SBRT of apically located lung lesions
Lindberg K; Grozman V; Lindberg S; Lax I; Lewensohn R; Wersäll P
Article: CLINICAL PROTEOMICS. 2015;12(1):8
Proteomics profiling identify CAPS as a potential predictive marker of tamoxifen resistance in estrogen receptor positive breast cancer
Johansson HJ; Sanchez BC; Forshed J; Stal O; Fohlin H; Lewensohn R; Hall P; Bergh J; Lehtio J; Linderholm BK
Article: MOLECULAR CANCER THERAPEUTICS. 2014;13(12):2941-2954
Marine Sponge Cribrochalina vasculum Compounds Activate Intrinsic Apoptotic Signaling and Inhibit Growth Factor Signaling Cascades in Non-Small Cell Lung Carcinoma
Zovko A; Viktorsson K; Haag P; Kovalerchick D; Farnegardh K; Alimonti A; Ilan M; Carmeli S; Lewensohn R
Article: RADIOTHERAPY AND ONCOLOGY. 2014;113(3):303-309
Creating a data exchange strategy for radiotherapy research: Towards federated databases and anonymised public datasets
Skripcak T; Belka C; Bosch W; Brink C; Brunner T; Budach V; Buettner D; Debus J; Dekker A; Grau C; Gulliford S; Hurkmans C; Just U; Krause M; Lambin P; Langendijk JA; Lewensohn R; Luehr A; Maingon P; Masucci M; Niyazi M; Poortmans P; Simon M; Schmidberger H; Spezi E; Stuschke M; Valentini V; Verheij M; Whitfield G; Zackrisson B; Zips D; Baumann M
Article: UROLOGIC ONCOLOGY: SEMINARS AND ORIGINAL INVESTIGATIONS. 2014;32(8):1215-1224
Vascular endothelial growth factor receptor 2, but not S100A4 or S100A6 correlates with prolonged survival in advanced urothelial carcinoma
Shah C-H; Viktorsson K; Kanter L; Sherif A; Asmundsson J; Rosenblatt R; Lewensohn R; Ullen A
Article: INTERNATIONAL JOURNAL OF RADIATION BIOLOGY. 2014;90(8):718-726
Phosphoprotein analysis reveals MEK inhibition as a way to target non-small cell lung cancer tumor initiating cells
Lundholm L; Haag P; Juntti T; Lewensohn R; Viktorsson K
Article: CELL DEATH AND DISEASE. 2014;5(3):e1111
Harnessing the lysosome-dependent antitumor activity of phenothiazines in human small cell lung cancer
Zong D; Zielinska-Chomej K; Juntti T; Mork B; Lewensohn R; Haag P; Viktorsson K
Journal article: RADIOTHERAPY AND ONCOLOGY. 2014;111:s221
OC-0565: SPACE - A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC
Nyman J; Hallqvist A; Lund JA; Brustugun OT; Bergström P; Friesland S; Lewensohn R; Drugge N; Rylander H; Lax I
Journal article: BLOOD. 2013;122(21):2619
Gene Expression Analyses At Time Of Diagnosis Indicate Biomarkers Predictive Of Therapeutic Response In Acute Myeloid Leukemia
Lindberg ML; Hååg P; Moshfegh A; Kanter L; Bjorkholm M; Lewensohn R; Kristina V; Stenke L
Article: GENES CHROMOSOMES AND CANCER. 2013;52(10):895-911
miRNA-214 is related to invasiveness of human non-small cell lung cancer and directly regulates alpha protein kinase 2 expression
Salim H; Arvanitis A; de Petris L; Kanter L; Haag P; Zovko A; Ozata DM; Lui W-O; Lundholm L; Zhivotovsky B; Lewensohn R; Viktorsson K
Article: JOURNAL OF PROTEOME RESEARCH. 2013;12(9):3934-3943
Quantitative Proteomics Profiling of Primary Lung Adenocarcinoma Tumors Reveals Functional Perturbations in Tumor Metabolism
Pernemalm M; De Petris L; Branca RM; Forshed J; Kanter L; Soria J-C; Girard P; Validire P; Pawitan Y; van den Oord J; Lazar V; Pahlman S; Lewensohn R; Lehtio J
Article: CANCER. 2013;119(16):3076-3083
Multidrug resistance in relapsed acute myeloid leukemia: Evidence of biological heterogeneity
Patel C; Stenke L; Varma S; Lindberg ML; Bjorkholm M; Sjoberg J; Viktorsson K; Lewensohn R; Landgren O; Gottesman MM; Gillet J-P
Article: ACTA ONCOLOGICA. 2013;52(6):1189-1194
Validation of the 7th TNM classification for non-small cell lung cancer: A retrospective analysis on prognostic implications for operated node-negative cases
Bergman P; Brodin D; Lewensohn R; de Petris L
Article: MARINE DRUGS. 2013;11(7):2574-2594
APS8, a Polymeric Alkylpyridinium Salt Blocks α7 nAChR and Induces Apoptosis in Non-Small Cell Lung Carcinoma
Zovko A; Viktorsson K; Lewensohn R; Kolosa K; Filipic M; Xing H; Kem WR; Paleari L; Turk T
Article: ANTI-CANCER DRUGS. 2013;24(6):648-652
Clinical activity of sorafenib in a previously treated advanced urothelial cancer patient
Shah C-H; Viktorsson K; Sherif A; Kanter L; Gryback P; Lewensohn R; Sandstrom P; Nilsson S; Ullen A
Article: CLINICAL CANCER RESEARCH. 2013;19(11):3019-3031
In Vitro and In Vivo Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells
Chauhan D; Ray A; Viktorsson K; Spira J; Paba-Prada C; Munshi N; Richardson P; Lewensohn R; Anderson KC
Article: ENVIRONMENTAL AND MOLECULAR MUTAGENESIS. 2013;54(5):327-337
A role for Myh1 in DNA repair after treatment with strand-breaking and crosslinking chemotherapeutic agents
Jansson K; Alao JP; Viktorsson K; Warringer J; Lewensohn R; Sunnerhagen P
Article: CELL DEATH AND DISEASE. 2013;4(1):e478
Resistance to DNA-damaging treatment in non-small cell lung cancer tumor-initiating cells involves reduced DNA-PK/ATM activation and diminished cell cycle arrest
Lundholm L; Haag P; Zong D; Juntti T; Mork B; Lewensohn R; Viktorsson K
Article: CELL DEATH AND DISEASE. 2013;4(1):e454
Inhibition of Ephrin B3-mediated survival signaling contributes to increased cell death response of non-small cell lung carcinoma cells after combined treatment with ionizing radiation and PKC 412
Stahl S; Kaminskyy VO; Efazat G; Vaculova AH; Rodriguez-Nieto S; Moshfegh A; Lewensohn R; Viktorsson K; Zhivotovsky B
Article: JOURNAL OF CONTEMPORARY BRACHYTHERAPY. 2012;4(4):205-212
Biological effective dose evaluation and assessment of rectal and bladder complications for cervical cancer treated with radiotherapy and surgery
Beskow C; Agren-Cronqvist A-K; Lewensohn R; Toma-Dasu I
Article: BRITISH JOURNAL OF CANCER. 2012;107(8):1361-1373
miRNA-214 modulates radiotherapy response of non-small cell lung cancer cells through regulation of p38MAPK, apoptosis and senescence
Salim H; Akbar NS; Zong D; Vaculova AH; Lewensohn R; Moshfegh A; Viktorsson K; Zhivotovsky B
Journal article: ANNALS OF ONCOLOGY. 2012;23:v38
P4.02 Proteomics Anchored Systems Biology Analysis of Prognostic Factors in Primary Lung Adenocarcinoma Tumours
Pernemalm A; Branca M; Petris DE; Forshed J; Lewensohn R; Besse B; Lazar V; Van den Oord J; Pawitan Y; Lehtiö J
Journal article: RADIOTHERAPY AND ONCOLOGY. 2012;103:s439-s440
EP-1142 BED DEPENDENCE OF LOCAL CONTROL AND LATE TOXICITY FOR CERVICAL CANCER TREATED WITH RADIOTHERAPY AND SURGERY
Beskow C; Ågren-Cronqvist AK; Lewensohn R; Toma-Dasu I
Journal article: MOLECULAR CANCER THERAPEUTICS. 2011;10(11_Supplement):b60
Abstract B60: Phenothiazines inhibits repair of chemotherapy-induced DNA double-strand break in tumor but not in normal fibroblasts by modulating chromatin configuration.
Zong D; Haag P; Yakymovych I; Lundholm L; Lewensohn R; Viktorsson K
Journal article: MOLECULAR CANCER THERAPEUTICS. 2011;10(11_Supplement):b40
Abstract B40: The melphalan prodrug melphalan-flufenamide shows cytotoxic effect in bladder cancer cell lines and triggers JNK and caspase-3 mediated apoptotic signaling.
Juntti T; Zakharchenko O; Haag P; Zong D; Laitinen S; Larsson R; Spira J; Lewensohn R; Viktorsson K; Ullen A
Journal article: MOLECULAR CANCER THERAPEUTICS. 2011;10(11_Supplement):a24
Abstract A24: Biomarker analysis and the role of caspase-2 in apoptotic signaling in AML cells.
Haag P; Lindberg ML; Kanter L; Lewensohn R; Stenke L; Viktorsson K; Olsson M; Zhivotovsky B
Journal article: MOLECULAR CANCER THERAPEUTICS. 2011;10(11_Supplement):b52
Abstract B52: A phase I-IIA, dose-escalating study of intravenous melphalan-flufenamide (J1) in adult patients with advanced solid tumors (I), advanced ovarian cancer, or non-small cell lung cancer (IIA).
Gullbo J; Berglund A; Ullen A; Larsson R; Lewensohn R; Nygren P; Spira J
Article: RADIOTHERAPY AND ONCOLOGY. 2011;101(2):260-266
Toxicity after reirradiation of pulmonary tumours with stereotactic body radiotherapy
Peulen H; Karlsson K; Lindberg K; Tullgren O; Baumann P; Lax I; Lewensohn R; Wersall P
Journal article: JOURNAL OF PROTEOME RESEARCH. 2011;10(10):4884
Phosphoproteomic Profiling of NSCLC Cells Reveals That Ephrin B3 Regulates Pro-survival Signaling through Aktl-Mediated Phosphorylation of the EphA2 Receptor (vol 10, pg 2566, 2011)
Stahl S; Branca RM; Efazat G; Ruzzene M; Zhivotovsky B; Lewensohn R; Viktorsson K; Lehtio J
Article: GENES & DEVELOPMENT. 2011;25(19):2031-2040
Essential role for DNA-PK-mediated phosphorylation of NR4A nuclear orphan receptors in DNA double-strand break repair
Malewicz M; Kadkhodaei B; Kee N; Volakakis N; Hellman U; Viktorsson K; Leung CY; Chen B; Lewensohn R; van Gent DC; Chen DJ; Perlmann T
Article: CELL DEATH AND DISEASE. 2011;2(7):e181
Chemosensitization by phenothiazines in human lung cancer cells: impaired resolution of γH2AX and increased oxidative stress elicit apoptosis associated with lysosomal expansion and intense vacuolation
Zong D; Haag P; Yakymovych I; Lewensohn R; Viktorsson K
Article: JOURNAL OF PROTEOME RESEARCH. 2011;10(5):2566-2578
Phosphoproteomic Profiling of NSCLC Cells Reveals that Ephrin B3 Regulates Pro-survival Signaling through Akt1-Mediated Phosphorylation of the EphA2 Receptor
Stahl S; Branca RM; Efazat G; Ruzzene M; Zhivotovsky B; Lewensohn R; Viktorsson K; Lehtio J
Article: ACTA ONCOLOGICA. 2011;50(4):518-527
NTCP modelling of lung toxicity after SBRT comparing the universal survival curve and the linear quadratic model for fractionation correction
Wennberg BM; Baumann P; Gagliardi G; Nyman J; Drugge N; Hoyer M; Traberg A; Nilsson K; Morhed E; Ekberg L; Wittgren L; Lund J-A; Levin N; Sederholm C; Lewensohn R; Lax I
Article: EUROPEAN JOURNAL OF CANCER. 2011;47(1):131-137
Diagnostic and prognostic role of plasma levels of two forms of cytokeratin 18 in patients with non-small-cell lung cancer
De Petris L; Branden E; Herrmann R; Sanchez BC; Koyi H; Linderholm B; Lewensohn R; Linder S; Lehtio J
Journal article: BLOOD. 2010;116(21):2491
Individualized Multidrug Resistance In Acute Myeloid Leukemia
Patel C; Gillet J-P; Stenke L; Lindberg M; Bjorkholm M; Sjoberg J; Viktorsson K; Lewensohn R; Landgren O; Gottesman MM
Journal article: BLOOD. 2010;116(21):1838
Anti-Myeloma Activity of Enzymatically Activated Melphalan Prodrug J1
Chauhan D; Bandi M; Singh AV; Podar K; Richardson PG; Munshi NC; Viktorsson K; Lewensohn R; Spira J; Anderson KC
Article: BIOCHEMICAL PHARMACOLOGY. 2010;79(9):1281-1290
The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan
Wickstrom M; Viktorsson K; Lundholm L; Aesoy R; Nygren H; Sooman L; Fryknas M; Vogel LK; Lewensohn R; Larsson R; Gullbo J
Journal article: CANCER RESEARCH. 2010;70(8_Supplement):684
Abstract 684: Trifluoperazine modulates DNA damage-induced cell death in human lung cancer cells through inhibition of DNA repair, cell cycle delays, and augmentation of pro-apoptotic signaling
Zong D; Hååg P; Yakymovych I; Lewensohn R; Viktorsson K
Article: PROTEOME SCIENCE. 2010;8:9
A novel method for sample preparation of fresh lung cancer tissue for proteomics analysis by tumor cell enrichment and removal of blood contaminants
De Petris L; Pernemalm M; Elmberger G; Bergman P; Orre L; Lewensohn R; Lehtio J
Journal article: MOLECULAR CANCER THERAPEUTICS. 2009;8(12_Supplement):b187
Abstract B187: Role of aminopeptidase N in the activation of the alkylating prodrug J1
Wickström M; Viktorsson K; Lundholm L; Aesoy R; Nygren H; Sooman L; Fryknäs M; Lewensohn R; Larsson R; Gullbo J
Journal article: MOLECULAR CANCER THERAPEUTICS. 2009;8(12_Supplement):b25
Abstract B25: Apoptotic signaling in AML cells after therapy with the monoclonal antibody-therapeutic gemtuzumab ozogamicin
Haag P; Lindberg ML; Kanter L; Lewensohn R; Stenke L; Viktorsson K
Journal article: BLOOD. 2009;114(22):3466
Gene Array Biomarkers in Acute Myeloid Leukemia to Predict Remission Duration.
Lindberg ML; Hååg P; Moshfegh A; Kanter L; Lewensohn R; Viktorsson K; Stenke L
Article: ANNALS OF ONCOLOGY. 2009;20(10):1639-1646
Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer
Linderholm BK; Hellborg H; Johansson U; Elmberger G; Skoog L; Lehtio J; Lewensohn R
Article: BRITISH JOURNAL OF CANCER. 2009;101(5):816-821
Radioresistant cervical cancer shows upregulation of the NHEJ proteins DNA-PKcs, Ku70 and Ku86
Beskow C; Skikuniene J; Holgersson A; Nilsson B; Lewensohn R; Kanter L; Viktorsson K
Article: JOURNAL OF CLINICAL ONCOLOGY. 2009;27(20):3290-3296
Outcome in a Prospective Phase II Trial of Medically Inoperable Stage I Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiotherapy
Baumann P; Nyman J; Hoyer M; Wennberg B; Gagliardi G; Lax I; Drugge N; Ekberg L; Friesland S; Johansson K-A; Lund J-A; Morhed E; Nilsson K; Levin N; Paludan M; Sederholm C; Traberg A; Wittgren L; Lewensohn R
Article: PROTEOMICS. 2009;9(13):3414-3424
Use of narrow-range peptide IEF to improve detection of lung adenocarcinoma markers in plasma and pleural effusion
Pernemalm M; De Petris L; Eriksson H; Branden E; Koyi H; Kanter L; Lewensohn R; Lehtio J
Article: EXPERIMENTAL HEMATOLOGY. 2009;37(6):755-766
Deficient activation of Bak and Bax confers resistance to gemtuzumab ozogamicin-induced apoptotic cell death in AML
Haag P; Viktorsson K; Lindberg ML; Kanter L; Lewensohn R; Stenke L
Article: MOLECULAR & CELLULAR PROTEOMICS. 2009;8(5):1117-1129
Proteomics and Pathway Analysis Identifies JNK Signaling as Critical for High Linear Energy Transfer Radiation-induced Apoptosis in Non-small Lung Cancer Cells
Stahl S; Fung E; Adams C; Lengqvist J; Mork B; Stenerlow B; Lewensohn R; Lehtio J; Zubarev R; Viktorsson K
Article: JOURNAL OF CHROMATOGRAPHY B: ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES. 2009;877(13):1306-1316
Robustness and accuracy of high speed LC-MS separations for global peptide quantitation and biomarker discovery
Lengqvist J; Andrade J; Yang Y; Alvelius G; Lewensohn R; Lehtio J
Article: JOURNAL OF NEURO-ONCOLOGY. 2009;92(2):137-147
Growth factor receptors signaling in glioblastoma cells: therapeutic implications
Carapancea M; Alexandru O; Fetea AS; Dragutescu L; Castro J; Georgescu A; Popa-Wagner A; Backlund ML; Lewensohn R; Dricu A
Article: LUNG CANCER. 2009;63(3):410-417
Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer
De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtio J
Journal article: BLOOD. 2008;112(11):5041
The Importance of CD33 Expression and Pro-Apoptotic Signalling for Gemtuzumab Ozogamicin-Induced Cytotoxic Effects on AML Cells
Lindberg ML; Hååg P; Viktorsson K; Kanter L; Lewensohn R; Stenke L
Journal article: BLOOD. 2008;112(11):4854
Analysis of γH2AX and NHEJ Signaling as Molecular Determinants for GOSensitivity in AML
Hååg P; Lindberg ML; Kanter L; Lewensohn R; Stenke L; Viktorsson K
Article: MOLECULAR CANCER RESEARCH. 2008;6(10):1630-1638
An Autocrine VEGF/VEGFR2 and p38 Signaling Loop Confers Resistance to 4-Hydroxytamoxifen in MCF-7 Breast Cancer Cells
Aesoy R; Sanchez BC; Norum JH; Lewensohn R; Viktorsson K; Linderholm B
Article: APMIS. 2008;116(10):888-895
Heat shock proteins 27, 60 and 70 as prognostic markers of prostate cancer
Glaessgen A; Jonmarker S; Lindberg A; Nilsson B; Lewensohn R; Ekman P; Valdman A; Egevad L
Article: RADIOTHERAPY AND ONCOLOGY. 2008;88(3):359-367
Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer - A first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study
Baumann P; Nyman J; Hoyer M; Gagliardi G; Lax I; Wennberg B; Drugge N; Ekberg L; Friesland S; Johansson K-A; Lund J-A; Morhed E; Nilsson K; Levin N; Paludan M; Sederholm C; Traberg A; Wittgren L; Lewensohn R
Article: JOURNAL OF PROTEOME RESEARCH. 2008;7(7):2712-2722
Evaluation of three principally different intact protein prefractionation methods for plasma biomarker discovery
Pernemalm M; Orre LM; Lengqvist J; Wikstrom P; Lewensohn R; Lehtio J
Article: JOURNAL OF PROTEOME RESEARCH. 2008;7(6):2332-2341
Proteomic data analysis workflow for discovery of candidate biomarker peaks predictive of clinical outcome for patients with acute myeloid leukemia
Forshed J; Pernemalm M; Tan CS; Lindberg M; Kanter L; Pawitan Y; Lewensohn R; Stenke L; Lehtio J
Article: APMIS. 2008;116(6):491-498
Expression of PDX-1 in prostate cancer, prostatic intraepithelial neoplasia and benign prostatic tissue
Jonmarker S; Glaessgen A; Culp WD; Pisa P; Lewensohn R; Ekman P; Valdman A; Egevad L
Article: MOLECULAR & CELLULAR PROTEOMICS. 2007;6(12):2122-2131
Up-regulation, modification, and translocation of S100A6 induced by exposure to ionizing radiation revealed by proteomics profiling
Orre LM; Pernemalm M; Lengqvist J; Lewensohn R; Lehtio J
Article: JOURNAL OF NEURO-ONCOLOGY. 2007;85(3):245-254
Dual targeting of IGF-1R and PDGFR inhibits proliferation in high-grade gliomas cells and induces radiosensitivity in JNK-1 expressing cells
Carapancea M; Cosaceanu D; Budiu R; Kwiecinska A; Tataranu L; Ciubotaru V; Alexandru O; Banita M; Pisoschi C; Baecklund ML; Lewensohn R; Dricu A
Article: MOLECULAR CANCER THERAPEUTICS. 2007;6(9):2409-2417
The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo
Wickstrom M; Johnsen JI; Ponthan F; Segerstrom L; Sveinbjornsson B; Lindskog M; Lovborg H; Viktorsson K; Lewensohn R; Kogner P; Larsson R; Gullbo J
Journal article: JOURNAL OF THORACIC ONCOLOGY. 2007;2(8):s751-s752
P3-169: A prospective phase II trial of stereotactic radiotherapy for early stage lung cancer–treatment feasibility and tumor response
Baumann P; Nyman J; Hoyer M; Nilsson K; Ekberg L; Lund J-Å; Friesland S; Paludan M; Lax I; Johansson K-A; Levin N; Morhed E; Gagliardi G; Wennberg B; Drugge N; Wittgren L; Traberg A; Sederholm C; Lewensohn R
Journal article: JOURNAL OF THORACIC ONCOLOGY. 2007;2(8):s536
P2-113: High-LET radiation activate apoptotic signaling through Bak/Bax and JNK in low-LET radiation resistant NSCLC cells
Viktorsson K; Ståhl S; Radulescu A-I; Mörk B; Stenerlöw B; Lewensohn R
Journal article: JOURNAL OF THORACIC ONCOLOGY. 2007;2(8):s614
P3-017: Characterization of efficacy and cellular signalling induced the novel melphalan pro-drug J1 and J3 in NSCLC cells
Viktorsson K; Wickström M; Häg P; Mörk B; Larsson R; Gullbo J; Lewensohn R
Article: MOLECULAR CANCER THERAPEUTICS. 2007;6(8):2303-2309
The antipsychotic drug trifluoperazine inhibits DNA repair and sensitizes non-small cell lung carcinoma cells to DNA double-strand break-induced cell death
Polischouk AG; Holgersson A; Zong D; Stenerlow B; Karlsson HL; Moller L; Viktorsson K; Lewensohn R
Article: ONCOGENE. 2007;26(17):2423-2434
Ionizing radiation activates IGF-1R triggering a cytoprotective signaling by interfering with Ku-DNA binding and by modulating Ku86 expression via a p38 kinase-dependent mechanism
Cosaceanu D; Budiu RA; Carapancea M; Castro J; Lewensohn R; Dricu A
Article: GROWTH FACTORS. 2007;25(1):1-8
Comparison of three approaches for inhibiting insulin-like growth factor I receptor and their effects on NSCLC cell lines in vitro
Cosaceanu D; Carapancea M; Alexandru O; Budiu R; Martinsson H-S; Starborg M; Vrabete M; Kanter L; Lewensohn R; Dricu A
Article: PROTEOMICS. 2006;6(23):6124-6133
Annotated regions of significance of SELDI-TOF-MS spectra for detecting protein biornarkers
Tan CS; Ploner A; Quandt A; Lehtio J; Pernemalm M; Lewensohn R; Pawitan Y
Article: JOURNAL OF BIOTECHNOLOGY. 2006;126(4):582-586
Pre-fractionation of archival frozen turnours for proteomics applications
Forsberg L; Larsson C; Sofiadis A; Lewensohn R; Hoog A; Lehtio J
Article: BRITISH JOURNAL OF CANCER. 2006;94(11):1683-1689
Expression of DNA damage response proteins and complete remission after radiotherapy of stage IB-IIA of cervical cancer
Beskow C; Kanter L; Holgersson A; Nilsson B; Frankendal B; Avall-Lundqvist E; Lewensohn R
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2006;342(4):1211-1217
p53 is involved in clearance of ionizing radiation-induced RAD51 foci in a human colon cancer cell line
Orre LM; Stenerlöw B; Dhar S; Larsson R; Lewensohn R; Lehtiö J
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2006;341(2):334-342
Rad51-related changes in global gene expression
Orre LM; Fält S; Szeles A; Lewensohn R; Wennborg A; Flygare J
Article: INTERNATIONAL JOURNAL OF RADIATION BIOLOGY. 2006;82(2):87-96
Evaluation of spectral karyotyping (SKY) in biodosimetry for the triage situation following gamma irradiation
Szeles A; Joussineau S; Lewensohn R; Lagercrantz S; Larsson C
Journal article: BLOOD. 2005;106(11):2367
Detection of Proteins Related to Therapeutic Outcome, Including Drug Resistance, in Acute Myeloid Leukemia Using Mass Spectrometry and Gel Based Proteomic Profiling.
Stenke L; Orre L; Dhar S; Larsson R; Lewensohn R; Lehtiö J
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2005;23(16_suppl):699
Protein profiles (proteomics) discriminating between effect/no effect of weekly paclitaxel: A phase II study in metastatic breast cancer (BC)
Linderholm BK; Lehtio J; Lidbrink E; Ekman E; Karlsson P; von Wachenfeldt A; Norberg B; Carlsson L; Hatschek T; Lewensohn R
Article: CANCER LETTERS. 2005;222(2):173-181
Modulation of response to radiation of human lung cancer cells following insulin-like growth factor 1 receptor inactivation
Cosaceanu D; Carapancea M; Castro J; Ekedahl J; Kanter L; Lewensohn R; Dricu A
Article: EXPERIMENTAL CELL RESEARCH. 2005;305(1):200-213
PKC 412 sensitizes U1810 non-small cell lung cancer cells to DNA damage
Hemström TH; Joseph B; Schulte G; Lewensohn R; Zhivotovsky B
Article: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2005;61(3):915-921
Different G₂/M accumulation in M059J and M059K cells after exposure to DNA double-strand break-inducing agents
Holgersson Å; Heiden T; Castro J; Edgren MR; Lewensohn R; Meijer AE
Article: MEDICAL ONCOLOGY. 2005;22(3):247-256
Therapeutic efficacy by recombinant human granulocyte/monocyte-colony stimulating factor on mucositis occurring in patients with oral and oropharynx tumors treated with curative radiotherapy -: A multicenter open randomized phase III study
Masucci G; Broman P; Kelly C; Lindahl S; Malmberg L; Reizenstein J; Ålenius M; Lewensohn R
Article: INVESTIGATIONAL NEW DRUGS. 2004;22(4):411-420
Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivo
Gullbo J; Lindhagen E; Bashir-Hassan S; Tullberg M; Ehrsson H; Lewensohn R; Nygren P; de la Torre M; Luthman K; Larsson R
Article: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2004;60(2):395-400
Long-term incidence of hypothyroidism after radiotherapy in patients with head-and-neck cancer
Tell R; Lundell G; Nilsson B; Sjödin H; Lewin F; Lewensohn R
Article: EXPERIMENTAL CELL RESEARCH. 2004;298(1):83-95
Endogenously released Smac is insufficient to mediate cell death of human lung carcinoma in response to etoposide
Bartling B; Lewensohn R; Zhivotovsky B
Article: EXPERIMENTAL AND MOLECULAR PATHOLOGY. 2004;77(1):1-6
Expression of DNA-PKcs and Ku86, but not Ku70, differs between lymphoid malignancies
Holgersson Å; Nilsson A; Lewensohn R; Kanter L
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2004;22(14_suppl):9615
Protein profiles (proteomics) discriminating between relapses versus relapse-free survival after adjuvant tamoxifen in 272 patients with primary estrogen receptor (ER) and progesterone receptor (PgR) positive breast cancer
Linderholm BK; Lehtio J; Ploner A; Pawitan Y; Skoog L; Lewensohn R
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2004;22(14_suppl):9615
Protein profiles (proteomics) discriminating between relapses versus relapse-free survival after adjuvant tamoxifen in 272 patients with primary estrogen receptor (ER) and progesterone receptor (PgR) positive breast cancer
Linderholm BK; Lehtio J; Ploner A; Pawitan Y; Skoog L; Lewensohn R
Article: CARCINOGENESIS. 2004;25(6):909-921
RasGTPase-activating protein is a target of caspases in spontaneous apoptosis of lung carcinoma cells and in response to etoposide
Bartling B; Yang JY; Michod D; Widmann C; Lewensohn R; Zhivotovsky B
Article: INTERNATIONAL JOURNAL OF RADIATION BIOLOGY. 2003;79(12):965-971
Difference in the induction, but not in the repair, of X-ray- and nitrogen ion-induced DNA single-strand breaks as measured using human cell extracts
Polischouk AG; Stenerlöw B; Edgren MR; Lewensohn R
Article: MOLECULAR CANCER THERAPEUTICS. 2003;2(12):1331-1339
Antitumor activity of the novel melphalan containing tripeptide J3 (L-prolyl-L-melphalanyl-p-L-fluorophenylalanine ethyl ester):: Comparison with its m-L-sarcolysin analogue P2
Gullbo J; Wallinder C; Tullberg M; Lövborg H; Ehrsson H; Lewensohn R; Nygren P; Luthman K; Larsson R
Article: CANCER BIOLOGY & THERAPY. 2003;2(6):663-669
Heat shock protein 72 does not modulate ionizing radiation-induced apoptosis in U1810 non-small cell lung carcinoma cells
Ekedahl J; Joseph B; Marchetti P; Fauvel H; Formstecher P; Lewensohn R; Zhivotovsky B
Article: EXPERIMENTAL CELL RESEARCH. 2003;289(2):256-264
Defective stress kinase and Bak activation in response to ionizing radiation but not cisplatin in a non-small cell lung carcinoma cell line
Viktorsson K; Ekedahl J; Lindebro MC; Lewensohn R; Zhivotovsky B; Linder S; Shoshan MC
Article: ANTI-CANCER DRUGS. 2003;14(8):617-624
Antitumor activity of the alkylating oligopeptides J1 (L-melphalanyl-p-L-fluorophenylalanine ethyl ester) and P2 (L-prolyl-m-L-sarcolysyl-p-L-fluorophenylalanine ethyl ester):: comparison with melphalan
Gullbo J; Dhar S; Luthman K; Ehrsson H; Lewensohn R; Nygren P; Larsson R
Article: INTERNATIONAL JOURNAL OF RADIATION BIOLOGY. 2003;79(8):611-621
Low and high LET radiation-induced apoptosis in M059J and M059K cells
Holgersson Å; Jernberg ARM; Persson LM; Edgren MR; Lewensohn R; Nilsson A; Brahme A; Meijer AE
Article: JOURNAL OF DRUG TARGETING. 2003;11(6):355-363
Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1
Gullbo J; Wickström M; Tullberg M; Ehrsson H; Lewensohn R; Nygren P; Luthman K; Larsson R
Article: ANTICANCER RESEARCH. 2003;23(3C):3077-3083
Radiation-induced cell cycle response in lymphocytes is not related to clinical side-effects in breast cancer patients
Tell R; Edgren MR; Sverrisdottir A; Castro J; Fornander T; Hansson LO; Skog S; Lewensohn R
Article: RADIATION RESEARCH. 2003;159(4):495-501
X-ray-induced DNA double-strand breaks in mouse L1210 cells: A new computational method for analyzing neutral filter elution data
Cedervall B; Edgren MR; Lewensohn R
Article: HEAD AND NECK. 2003;25(4):313-321
Expression of Ku86 confers favorable outcome of tonsillar carcinoma treated with radiotherapy
Friesland S; Kanter-Lewensohn L; Tell R; Munck-Wikland E; Lewensohn R; Nilsson A
Article: ONCOLOGY RESEARCH. 2003;14(3):113-132
Structure-activity relationship for alkylating dipeptide nitrogen mustard derivatives
Gullbo J; Tullberg M; Våbeno J; Ehrsson H; Lewensohn R; Nygren P; Larsson R; Luthman K
Article: EXPERIMENTAL CELL RESEARCH. 2002;279(2):277-290
Expression of inhibitor of apoptosis proteins in small- and non-small-cell lung carcinoma cells
Ekedahl J; Joseph B; Grigoriev MY; Müller M; Magnusson C; Lewensohn R; Zhivotovsky B
Article: CANCER LETTERS. 2002;180(2):191-194
Synthesis and cytotoxicity of the dihydrated complex of oxaliplatin
Videhult P; Yachnin J; Jerremalm E; Lewensohn R; Ehrsson H
Article: ANTICANCER RESEARCH. 2002;22(3):1787-1793
DNA-dependent protein kinase in leukaemia cells and correlation with drug sensitivity
Eriksson Å; Lewensohn R; Larsson R; Nilsson A
Article: LAKARTIDNINGEN. 2002;99(13):1453-1455
[Management of radiation injuries--new organization, new guidelines].
Lewensohn R; Joussineau S; Stenke L
Article: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 2002;12(2):158-170
Pathologic complete remission after preoperative intracavitary radiotherapy of cervical cancer stage Ib and IIa is a strong prognostic factor for long-term survival:: analysis of the Radiumhemmet data 1989-1991
Beskow C; Ågren-Cronqvist AK; Granath F; Frankendal B; Lewensohn R
Journal article: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 2002;12(2):158-170
Pathologic complete remission after preoperative intracavitary radiotherapy of cervical cancer stage Ib and IIa is a strong prognostic factor for long-term survival: analysis of the Radiumhemmet data 1989–1991
Beskow C; Ågren-Cronqvist A-K; Granath F; Frankendal B; Lewensohn R
Article: ONCOGENE. 2002;21(1):65-77
Mitochondrial dysfunction is an essential step for killing of non-small cell lung carcinomas resistant to conventional treatment
Joseph B; Marchetti P; Formstecher P; Kroemer G; Lewensohn R; Zhivotovsky B
Article: NUCLEAR INSTRUMENTS AND METHODS IN PHYSICS RESEARCH, SECTION B: BEAM INTERACTIONS WITH MATERIALS AND ATOMS. 2001;184(4):569-588
Design of a centre for biologically optimised light ion therapy in Stockholm
Brahme A; Lewensohn R; Ringborg U; Amaldi U; Gerardi F; Rossi S
Article: ONCOGENE. 2001;20(23):2877-2888
Defective caspase-3 relocalization in non-small cell lung carcinoma
Joseph B; Ekedahl J; Lewensohn R; Marchetti P; Formstecher P; Zhivotovsky B
Article: LAKARTIDNINGEN. 2001;98(21):2565-2566
[Not proved that depleted uranium has negative effects on health].
Joussineau S; Lewensohn R
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2001;283(4):726-731
DNA-dependent protein kinase is inhibited by trifluoperazine
Eriksson Å; Yachnin J; Lewensohn R; Nilsso A
Article: INTERNATIONAL JOURNAL OF RADIATION BIOLOGY. 2001;77(3):309-317
High-LET radiation induces apoptosis in lymphoblastoid cell lines derived from ataxia-telangiectasia patients
Meijer AE; Ekedahl J; Joseph B; Castro J; Harms-Ringdahl M; Zhivotovsky B; Lewensohn R
Article: INTERNATIONAL JOURNAL OF CANCER. 2001;96:43-53
Radiosensitivity of human squamous carcinoma cell lines is associated with amount of spontaneous DNA strand breaks
Polischouk AG; Grénman R; Granath F; Lewensohn R
Article: ACTA ONCOLOGICA. 2001;40(5):566-573
A Swedish study of chemoradiation in squamous cell carcinoma of the esophagus
Stockeld D; Tennvall J; Wagenius G; Albertsson M; Backman L; Brodin O; Cwikiel M; Granström L; Gustafsson G; Gustavsson S; Hambraeus G; Lewensohn R; Sjöstedt S; Strander H; Åberg B; Fagerberg J
Article: ANTICANCER RESEARCH. 2001;21(1B):529-534
Human papilloma virus (HPV) and p53 immunostaining in advanced tonsillar carcinoma - Relation to radiotherapy response and survival
Friesland S; Mellin H; Munck-Wikland E; Nilsson A; Lindholm J; Dalianis T; Lewensohn R
Article: INTERNATIONAL JOURNAL OF RADIATION BIOLOGY. 2001;77(1):127-135
Cellular effects of high-intensity focused continuous wave ultrasound alone and in combination with X-rays
Jernberg A; Edgren MR; Lewensohn R; Wiksell H; Brahme A
Article: CANCER RESEARCH. 2000;60(22):6230-6235
Frequent amplification of the Telomerase Reverse Transcriptase gene in human tumors
Zhang AJ; Zheng CY; Lindvall C; Hou M; Ekedahl J; Lewensohn R; Yan ZQ; Yang XY; Henriksson M; Blennow E; Nordenskjöld M; Zetterberg A; Björkholm M; Gruber A; Xu DW
Journal article: LUNG CANCER. 2000;29(1):162
DNA repair — A determinant for sensitivity to radiation in lungcancer?
Lewensohn R; Ekedahl J; Joseph B; Nilsson A; Polischouk A; Sirzén F; Zhivotovsky B
Article: ANTICANCER RESEARCH. 2000;20(5A):3051-3058
Expression and activity of DNA-dependent protein kinase in normal human leukocytes
Eriksson Å; Lewensohn R; Nilsson A
Article: INTERNATIONAL JOURNAL OF CANCER. 2000;89(3):300-304
Human papillomavirus (HPV) DNA in tonsillar cancer: Clinical correlates, risk of relapse, and survival
Mellin H; Friesland S; Lewensohn R; Dalianis T; Munck-Wikland E
Article: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 1999;45(5):1259-1266
Prognostic impact of complete remission after preoperative irradiation of tonsillar carcinoma: A retrospective analysis of the radiumhemmet data, 1980-1995
Friesland S; Fernberg JO; Lundell G; Munck-Wikland E; Strander H; Lewensohn R
Article: ANTI-CANCER DRUGS. 1999;10(10):921-928
In vitro cellular accumulation and cytotoxicity of liposomal and conventional formulations of daunorubicin and doxorubicin in resistant K562 cells
Wang YY; Eksborg S; Lewensohn R; Lindberg A; Liliemark E
Article: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 1999;45(4):1005-1010
The immunohistochemical expression of DNA-PKCS and Ku (p70/p80) in head and neck cancers:: Relationships with radiosensitivity
Björk-Eriksson T; West C; Nilsson A; Magnusson B; Svensson M; Karlsson E; Slevin N; Lewensohn R; Mercke C
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 1999;262(2):381-387
Differences in expression of pro-caspases in small cell and non-small cell lung carcinoma
Joseph B; Ekedahl J; Sirzen F; Lewensohn R; Zhivotovsky B
Article: CELL PROLIFERATION. 1999;32(4):239-248
Cell cycle-dependent regulation of the DSA-dependent protein kinase
Nilsson A; Sirzén F; Lewensohn R; Wang N; Skog S
Article: INTERNATIONAL JOURNAL OF RADIATION BIOLOGY. 1999;75(6):709-716
Epstein-Barr virus-transformed lymphoblastoid cell lines of ataxia telangiectasia patients are defective in X-ray-induced apoptosis
Meijer AE; Zhivotovsky B; Lewensohn R
Article: MUTATION RESEARCH - FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS. 1999;425(1):9-20
Chromosomal sensitivity to X-ray irradiation during the G₂ phase in lymphocytes of patients with hereditary cutaneous malignant melanoma as compared to healthy controls
Andersson HC; Lewensohn R; Månsson-Brahme E
Article: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 1999;43(1):191-198
Dna double-strand break repair, DNA-PK, and DNA ligases in two human squamous carcinoma cell lines with different radiosensitivity
Polischouk AG; Cedervall B; Ljungquist S; Flygare J; Hellgren D; Grénman R; Lewensohn R
Article: EUROPEAN JOURNAL OF CANCER. 1999;35(1):111-116
DNA-dependent protein kinase content and activity in lung carcinoma cell lines:: Correlation with intrinsic radiosensitivity
Sirzén F; Nilsson A; Zhivotovsky B; Lewensohn R
Article: CANCER LETTERS. 1998;132(1-2):175-180
The kinetics and cytotoxicity of cisplatin and its monohydrated complex
Yachnin JR; Wallin I; Lewensohn R; Sirzén F; Ehrsson H
Article: LUNG CANCER. 1998;22(1):1-13
Higher spontaneous apoptotic index in small cell compared with non-small cell lung carcinoma cell lines;: lack of correlation with Bcl-2/Bax
Sirzén F; Zhivotovsky B; Nilsson A; Bergh J; Lewensohn R
Article: BRITISH JOURNAL OF CANCER. 1998;78(3):328-335
Comparison of the cytotoxic activity of melphalan with L-prolyl-m-L-sarcolysyl-L-p-fluorophenylalanine in human tumour cell lines and primary cultures of tumour cells from patients
Larsson R; Dhar S; Ehrsson H; Nygren P; Lewensohn R
Article: JOURNAL OF CLINICAL ONCOLOGY. 1998;16(3):1054-1059
Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer. Head and Neck Interferon Cooperative Study Group.
Schrijvers D; Johnson J; Jiminez U; Gore M; Kosmidis P; Szpirglas H; Robbins K; Oliveira J; Lewensohn R; Schüller J; Riviere A; Arvay C; Langecker P; Jacob H; Cvitkovic E; Vokes E
Article: ANTICANCER RESEARCH. 1998;18(2A):695-699
Spontaneous and radiation-induced apoptosis in lung carcinoma cells with different intrinsic radiosensitivities
Sirzén F; Zhivotovsky B; Nilsson A; Bergh J; Lewensohn R
Article: INTERNATIONAL JOURNAL OF RADIATION BIOLOGY. 1998;73(2):169-177
RBE for the induction of apoptosis in human peripheral lymphocytes exposed in vitro to high-LET radiation generated by accelerated nitrogen ions
Meijer AE; Kronqvist USE; Lewensohn R; Harms-Ringdahl M
Article: BRITISH JOURNAL OF CANCER. 1998;77(4):643-649
Comparison between radiation-induced cell cycle delay in lymphocytes and radiotherapy response in head and neck cancer
Tell R; Heiden T; Granath F; Borg AL; Skog S; Lewensohn R
Article: ANTICANCER RESEARCH. 1997;17(5A):3381-3386
Characterisation of the G1/S cell cycle checkpoint defect in lung carcinoma cells with different intrinsic radiosensitivities
Sirzen F; Heiden T; Nilsson A; Bergh J; Skog S; Lewensohn R
Journal article: LUNG CANCER. 1997;18:166-167
651 Apoptosis in SCLC cell lines; relation to intrinsic radiosensitivity
Sirzén F; Nilsson A; Zhivotovsky B; Bergh J; Lewensohn R
Article: EUROPEAN JOURNAL OF CANCER. 1997;33(6):942-949
Response to radiotherapy of human uterine cervix carcinoma is not correlated with rearrangements of the Ha-ras-1 and/or c-myc genes
Polischouk AG; Scotnikova OI; Sergeeva NS; Zharinov GM; Lewensohn R; Zhivotovsky B
Article: CANCER EPIDEMIOLOGY. 1997;21(1):91-102
Kinetics of G1/S and G2/M transition in X-irradiated ataxia-telangiectasia cells
Skog S; Lewensohn R; He QM; Borg AL; Gatti R
Article: JOURNAL OF PHARMACEUTICAL SCIENCES. 1996;85(8):824-827
Pharmacokinetics of cisplatin and its monohydrated complex in humans
Andersson A; Fagerberg J; Lewensohn R; Ehrsson H
Journal article: LAKARTIDNINGEN. 1995;92(44):4100-4105
[From Hiroshima to Chernobyl. Increasing number of late fatal cases of cancer].
Drottz-Sjöberg BM; Engstedt L; Hall P; Lewensohn R; Valentin J
Journal article: LUNG CANCER. 1994;11(5-6):393-400
DOSE INTENSITY OF THE CAVE REGIMEN IN SMALL-CELL LUNG-CANCER CORRELATES TO RESPONSE RATE
SIRZEA F; WESTBERG R; LEWENSOHN R; BILLING B
Journal article: RADIATION RESEARCH. 1994;139(1):34-39
LESS INITIAL REJOINING OF X-RAY-INDUCED DNA DOUBLE-STRAND BREAKS IN CELLS OF A SMALL-CELL (U-1285) COMPARED TO A LARGE-CELL (U-1810) LUNG-CARCINOMA CELL-LINE
CEDERVALL B; SIRZEA F; BRODIN O; LEWENSOHN R
Journal article: LAKARTIDNINGEN. 1994;91(22):2243-2246
[Views on handling of esophageal cancer. Better prognosis with new methods?].
Stockeld D; Fagerberg J; Backman L; Lewensohn R; Granström L
Journal article: LUNG CANCER. 1994;11:111
A phase II trial of carboplatin (CA) and vindesine (V) in advanced adenocarcinoma of the lung
Sederholm C; Lewensohn R; Agrenius V; Malmström A; Sirzea F; Thaning L; Ericsson B
Journal article: ACTA ONCOLOGICA. 1994;33(4):439-450
COMBINED TREATMENT MODALITIES IN ESOPHAGEAL CANCER - SHOULD CHEMOTHERAPY BE INCLUDED
FAGERBERG J; STOCKELD D; LEWENSOHN R
Journal article: EUROPEAN JOURNAL OF CANCER. 1994;30A(5):710-713
EUROPEAN-SCHOOL-OF-ONCOLOGY FIRST EURO-AMERICAN FORUM ON LUNG-CANCER TREATMENT
BUNN PA; VANZANDWIJK N; PASTORINO U; AISNER J; ALBERTO P; ARRIAGADA R; CARNEY D; CORNIS R; DITTRICH C; GATZEMEIER U; GINSBERG R; GRECO FA; HANSEN HH; HARPER P; HENRIKSSON R; HUBER H; KLENER P; LECHEVALIER T; LEWENSOHN R; MURRAY N; NIEDERLE N; POSTMUS P; ROSELL R; SCAGLIOTTI G; SCULIER JP; SPLINTER T; STAHEL R; SYMANN M; THATCHER N; TONATO M; TURRISI A
Journal article: EUROPEAN JOURNAL OF CANCER. 1993;29:s219
Studies on c-Ha-RAS and c-MOS oncogene rearrangements in human uterine cervix carcinomas differing in radiosensitivity
Polischuk A; Lewensohn R; Zhivotovsky B
Journal article: EUROPEAN JOURNAL OF CANCER. 1993;29:s124
Cancer in Sweden derived from fallout after the chernobyl accident
Ekman M; Moberg L; Stenke L; Lewensohn R; Reizenstein P
Journal article: EUROPEAN JOURNAL OF CANCER. 1993;29:s227
Incidence of hypothyroidism in patients treated for head and neck cancer by conventional radiotherapy
Lewensohn R; Lundell G; Sventelius M
Journal article: CANCER CHEMOTHERAPY AND PHARMACOLOGY. 1993;31(4):265-268
PHARMACOKINETICS OF PEPTICHEMIO IN MYELOMA PATIENTS - RELEASE OF M-L-SARCOLYSIN INVIVO AND INVITRO
EHRSSON H; LEWENSOHN R; WALLIN I; HELLSTROM M; MERLINI G; JOHANSSON B
Journal article: EUROPEAN JOURNAL OF CANCER. 1993;29:s166
Neuropathy during treatment with vindesine and carbo-platin in patients with adenocarcinoma of the lung
Borg J; Borg K; Hasson S; Agrenius V; Lewensohn R
Journal article: ACTA ENDOCRINOLOGICA. 1992;127(4):294-300
PARATHYROID HORMONE-RELATED PEPTIDE, MEASURED BY A MIDMOLECULE RADIOIMMUNOASSAY, IN VARIOUS HYPERCALCEMIC AND NORMOCALCEMIC CONDITIONS
BUCHT E; EKLUND A; TOSS G; LEWENSOHN R; GRANBERG B; SJOSTEDT U; EDDELAND R; TORRING O
Journal article: LAKARTIDNINGEN. 1992;89(17):1480-1484
[Ultraviolet rays can cause skin cancer. Cumulative effect of physical and biological factors].
Lewensohn R; Ringborg U; Wester U
Journal article: ANTI-CANCER DRUGS. 1991;2(6):565-570
INTERACTION OF MELPHALAN AND DEXAMETHASONE IN A HUMAN MYELOMA CELL-LINE
FERNBERG JO; LEWENSOHN R; SKOG S
Journal article: EUROPEAN JOURNAL OF HAEMATOLOGY. 1991;47(3):161-167
CELL-CYCLE ARREST AND DNA DAMAGE AFTER MELPHALAN TREATMENT OF THE HUMAN MYELOMA CELL-LINE RPMI-8226
FERNBERG JO; LEWENSOHN R; SKOG S
Journal article: ANTICANCER RESEARCH. 1991;11(5):1725-1730
CYTOTOXICITY AND DNA CROSS-LINKING INDUCED BY PEPTIDE CONJUGATED META-L-SARCOLYSIN IN HUMAN-MELANOMA CELLS
HANSSON J; LEWENSOHN R; RINGBORG U
Journal article: LUNG CANCER. 1991;7:127
Dose intensity (DI) of the CAVE regimen in SCLC is important for achieving a higher response rate (R)
Sirzea F; Lewensohn R; Westerberg R
Journal article: ANTICANCER RESEARCH. 1991;11(1):321-324
INCREASED TOXICITY AND DNA CROSS-LINKING BY PEPTIDE BOUND M-L-SARCOLYSIN (PEPTICHEMIO) AS COMPARED TO MELPHALAN AND M-L-SARCOLYSIN IN HUMAN-MELANOMA CELL-LINES
LEWENSOHN R; EHRSSON H; HANSSON J; RINGBORG U
Journal article: MEDICAL ONCOLOGY AND TUMOR PHARMACOTHERAPY. 1991;8(4):265-269
EFFICACY OF PEPTIDE BOUND M-L-SARCOLYSIN (PEPTICHEMIO) ON MELPHALAN RESISTANT HUMAN MYELOMA CELLS-INVITRO
LEWENSOHN R; FERNBERG JO; EHRSSON H; MERLINI G
Journal article: MEDICAL ONCOLOGY AND TUMOR PHARMACOTHERAPY. 1991;8(2):63-67
INTERPHASE CELL-DEATH AS RELATED TO THE CELL-CYCLE OF MELPHALAN-TREATED HUMAN MYELOMA CELLS
FERNBERG JO; LEWENSOHN R; SKOG S
Journal article: EUROPEAN JOURNAL OF CANCER. 1990;26(3):393-396
ORAL DOSAGE OF MELPHALAN AND RESPONSE TO TREATMENT IN MULTIPLE-MYELOMA
FERNBERG JO; JOHANSSON B; LEWENSOHN R; MELLSTEDT H
Journal article: ANTICANCER RESEARCH. 1990;10(2A):297-301
MELPHALAN-INDUCED DNA CROSS-LINKING AND INHIBITION OF DNA AND RNA-SYNTHESIS IN HUMAN-MELANOMA AND LYMPHOBLAST CELLS
RINGBORG U; HANSSON J; JUNGNELIUS U; LEWENSOHN R; SKOG S
Journal article: EUROPEAN JOURNAL OF CANCER AND CLINICAL ONCOLOGY. 1988;24(9):1505-1510
INTERFERON EXERTS A CYTO-TOXIC EFFECT ON PRIMARY HUMAN MYELOMA CELLS
EINHORN S; FERNBERG JO; GRANDER D; LEWENSOHN R
Journal article: ACTA ONCOLOGICA. 1988;27(4):383-392
CIS-DIAMMINEDICHLOROPLATINUM(II) TOXICITY IN HUMAN-MELANOMA CELLS AND LYMPHOCYTES AS RELATED TO CELLULAR PLATINUM ACCUMULATION, DNA CROSS-LINKING AND INHIBITION OF DNA-SYNTHESIS
HANSSON J; LEWENSOHN R; RINGBORG U
Journal article: EUROPEAN JOURNAL OF CANCER AND CLINICAL ONCOLOGY. 1987;23(6):783-788
DIFFERENTIAL DNA CROSS-LINKING AND CYTOTOXICITY IN PHA-STIMULATED HUMAN-LYMPHOCYTES EXPOSED TO MELPHALAN, META-L-SARCOLYSIN AND PEPTICHEMIO
LEWENSOHN R; HANSSON J; RINGBORG U; EHRSSON H
Journal article: CANCER RESEARCH. 1987;47(10):2631-2637
FORMATION AND REMOVAL OF DNA CROSS-LINKS INDUCED BY MELPHALAN AND NITROGEN-MUSTARD IN RELATION TO DRUG-INDUCED CYTOTOXICITY IN HUMAN-MELANOMA CELLS
HANSSON J; LEWENSOHN R; RINGBORG U; NILSSON B
Journal article: ANTICANCER RESEARCH. 1987;7(1):97-104
MELPHALAN-INDUCED DNA CROSS-LINKING IN HUMAN-MELANOMA CELLS AND PHYTOHEMAGGLUTININ-STIMULATED LYMPHOCYTES IN RELATION TO INTRACELLULAR DRUG CONTENT AND CELLULAR-LEVELS OF GLUTATHIONE
HANSSON J; EDGREN M; EHRSSON H; LEWENSOHN R; RINGBORG U
Journal article: PHOTO-DERMATOLOGY. 1985;2(6):401-406
MEASUREMENT OF DNA-REPAIR SYNTHESIS INDUCED BY ULTRAVIOLET-RADIATION
LEWENSOHN R; RINGBORG U
Journal article: ANTICANCER RESEARCH. 1985;5(5):471-477
DIFFERENT MELPHALAN TOXICITY AND DNA CROSS-LINKING IN HUMAN-MELANOMA CELLS AS COMPARED TO PHYTOHAEMAGGLUTININ-STIMULATED LYMPHOCYTES
HANSSON J; LEWENSOHN R; RINGBORG U
Journal article: MUTATION RESEARCH - FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS. 1983;111(2):171-184
DNA-REPAIR REPLICATION, DNA BREAKS AND SISTER-CHROMATID EXCHANGE IN HUMAN-CELLS TREATED WITH ADRIAMYCIN INVITRO
LAMBERT B; STEN M; SODERHALL S; RINGBORG U; LEWENSOHN R
Journal article: CANCER LETTERS. 1983;18(3):305-310
INHIBITION OF NITROGEN-MUSTARD INDUCED DNA-REPAIR SYNTHESIS BY ANTHRACYCLINES IN HUMAN PERIPHERAL LEUKOCYTES
LEWENSOHN R; RINGBORG U
Journal article: EUROPEAN JOURNAL OF CANCER AND CLINICAL ONCOLOGY. 1983;19(1):59-63
DNA CONTENT OF HUMAN MYELOMA CELLS
LEWENSOHN R; TRIBUKAIT B; HANSSON J
Journal article: ANALYTICAL AND QUANTITATIVE CYTOLOGY. 1982;4(2):99-104
FLOW CYTOFLUOROMETRIC DNA ANALYSES OF METASTASES OF HUMAN-MALIGNANT MELANOMAS
HANSSON J; TRIBUKAIT B; LEWENSOHN R; RINGBORG U
Journal article: SCANDINAVIAN JOURNAL OF HAEMATOLOGY. 1982;28(5):399-407
DNA-REPAIR SYNTHESIS IN BLAST CELLS FROM PATIENTS WITH ACUTE MYELOBLASTIC-LEUKEMIA
LEWENSOHN R; RINGBORG U
Journal article: JOURNAL OF CELL SCIENCE. 1982;54(APR):69-78
DNA-REPAIR SYNTHESIS IN SUB-POPULATIONS OF HUMAN-LYMPHOCYTES
LEWENSOHN R; RINGBORG U; BARAL E; LAMBERT B
Journal article: LAKARTIDNINGEN. 1982;79(10):904-905
[DNA repair in human cells - mechanisms and importance].
Lewensohn R; Ringborg U
Journal article: CANCER RESEARCH. 1982;42(1):84-88
DIFFERENT ACTIVITIES OF UNSCHEDULED DNA-SYNTHESIS IN HUMAN-MELANOMA AND BONE-MARROW CELLS
LEWENSOHN R; RINGBORG U; HANSSON J
Journal article: ACTA PATHOLOGICA ET MICROBIOLOGICA SCANDINAVICA - SECTION A PATHOLOGY. 1981;89(6):417-424
AN EBV-ASSOCIATED, SWEDISH CASE OF BURKITT-TYPE MALIGNANT-LYMPHOMA
BIBERFELD P; CHRISTENSSON B; ANDERSSONANVRET M; ERNBERG I; LEWENSOHN R; EKMAN M; JOHANSSON B; TRIBUKAIT B
Journal article: EUROPEAN JOURNAL OF CANCER AND CLINICAL ONCOLOGY. 1981;17(9):991-996
DNA-DAMAGE IN HUMAN-CELLS TREATED WITH THE CLOSELY RELATED ALKYLATING-AGENTS PEPTICHEMIO, M-L-SARCOLYSIN AND MELPHALAN
RINGBORG U; LAMBERT B; LEWENSOHN R; TURESSON I
Journal article: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 1981;76(4):268-270
DECREASED UV-INDUCED DNA-REPAIR SYNTHESIS IN PERIPHERAL LEUKOCYTES FROM PATIENTS WITH THE NEVOID BASAL-CELL CARCINOMA SYNDROME
RINGBORG U; LAMBERT B; LANDEGREN J; LEWENSOHN R
Journal article: ACTA MEDICA SCANDINAVICA. 1981;210(5):381-387
HUMAN-MONOCYTES AND LYMPHOCYTES DIFFER IN THE RATE OF DNA-REPAIR SYNTHESIS AND VIABILITY AFTER EXPOSURE TO NITROGEN-MUSTARD
LEWENSOHN R; RINGBORG U
Journal article: BLOOD. 1980;55(2):311-316
Induction of Unscheduled DNA Synthesis in Human Myeloma Cells
Lewensohn R; Ringborg U
Journal article: BLOOD. 1980;55(2):311-316
INDUCTION OF UNSCHEDULED DNA-SYNTHESIS IN HUMAN MYELOMA CELLS
LEWENSOHN R; RINGBORG U
Journal article: BLOOD. 1979;54(6):1320-1329
Induction of Unscheduled DNA Synthesis in Human Bone Marrow Cells by Bifunctional Alkylating Agents
Lewensohn R; Ringborg U
Journal article: BLOOD. 1979;54(6):1320-1329
INDUCTION OF UNSCHEDULED DNA-SYNTHESIS IN HUMAN-BONE MARROW-CELLS BY BIFUNCTIONAL ALKYLATING-AGENTS
LEWENSOHN R; RINGBORG U
Journal article: EXPERIMENTAL CELL RESEARCH. 1979;123(1):107-110
INCREASE OF UV-INDUCED DNA-REPAIR SYNTHESIS DURING BLAST-TRANSFORMATION OF HUMAN-LYMPHOCYTES
LEWENSOHN R; KILLANDER D; RINGBORG U; LAMBERT B
Journal article: ACTA MEDICA SCANDINAVICA. 1978;203(4):276-278
FACTORS RESPONSIBLE FOR BONE-MARROW TOXICITY AFTER TREATMENT OF MYELOMA PATIENTS WITH DIFFERENT ALKYLATING-AGENTS
RINGBORG U; LEWENSOHN R
Visa fler

Alla övriga publikationer

Review: MOLECULAR ONCOLOGY. 2024;18(11):2612-2628
Minimally invasive biopsy-based diagnostics in support of precision cancer medicine
Franzen B; Auer G; Lewensohn R
Preprint: MEDRXIV. 2024
Exploring the discrepancies between clinical trials and real-world data by accounting for Selection criteria, Operations, and Measurements of Outcome
Marzano L; Darwich AS; Dan A; Tendler S; Lewensohn R; De Petris L; Raghothama J; Meijer S
Corrigendum: CELL DEATH DISCOVERY. 2022;8(1):472
Proof-of-principle studies on a strategy to enhance nucleotide imbalance specifically in cancer cells (vol 15, pg 548, 2022)
Alkasalias T; Zhang J; Madapura H; Dalarun B; Reina OB; Lewensohn R; Viktorsson K; Salihi A; Darekar S; Lain S
Preprint: BIORXIV. 2022
Analyses of single extracellular vesicles from non-small lung cancer cells to reveal effects by Epidermal growth factor inhibitor treatments
Stridfeldt F; Cavallaro S; Hååg P; Lewensohn R; Linnros J; Viktorsson K; Dev A
Preprint: RESEARCH SQUARE. 2022
Proof-of-principle studies on a strategy to enhance nucleotide imbalance specifically in cancer cells
Lain S; Alkasalias T; Zhang J; Madapura H; Dalaroun B; Reina OB; Lewensohn R; Viktorsson K; Salihi A; Darekar S
Preprint: BIORXIV. 2022
Design and optimization of silicon-based electrokinetic microchip for sensitive detection of small extracellular vesicles
Gevari MT; Sahu SS; Stridfeldt F; Hååg P; Viktorsson K; Lewensohn R; Gori A; Cretich M; Dev A
Letter: ACTA ONCOLOGICA. 2022;61(7):869-873
Precision radiation of immune checkpoint therapy resistant melanoma metastases (PROMMEL study): study protocol for a phase II open-label multicenter trial
Backlund E; Yang M; Grozman V; Masucci G; Falkenius J; Eriksson H; Jovanovic B; Hammarlund K; Isacsson U; Radu C; Abel E; Karlsson K; Palanco Zamora R; Wersall P; Edback U; Wickstrom S; Darai Ramqvist E; Egyhazi Brage S; Kiessling R; Viktorsson K; Franzen B; Lewensohn R; Olofsson Bagge R; Ullenhag GJ; Ny L; Lindberg K; Helgadottir H
Letter: JOURNAL OF THORACIC ONCOLOGY. 2021;16(10):e81-e82
In Response to Rosenberg et al. "The Nordic-HILUS Trial: Ultracentral Lung SABR and a Narrow Therapeutic Window"
Lindberg K; Lax I; Karlsson K; Lewensohn R
Preprint: BIORXIV. 2021
SRF-CLICAL: an approach for patient risk stratification using random forest models
Simao FA; Hieta R; Pulman JA; Madonna G; Ascierto PA; Lewensohn R; Masucci GV
Preprint: BIORXIV. 2021
Multiplexed electrokinetic sensor for detection and therapy monitoring of extracellular vesicles from liquid biopsies of non-small-cell lung cancer patients
Cavallaro S; Hååg P; Sahu S; Berisha L; Kaminsky V; Ekman S; Lewensohn R; Linnros J; Viktorsson K; Dev A
Preprint: BIORXIV. 2021
High throughput imaging of nanoscale extracellular vesicles by scanning electron microscopy for accurate size-based profiling and morphological analysis
Cavallaro S; Hååg P; Viktorsson K; Krozer A; Fogel K; Lewensohn R; Linnros J; Dev A
Letter: ACTA ONCOLOGICA. 2020;59(1):28-32
Analysis of human papillomaviruses and human polyomaviruses in lung cancer from Swedish never-smokers
Ramqvist T; Ortiz-Villalon C; Branden E; Koyi H; de Petris L; Wagenius G; Brodin O; Reutersward C; Dalianis T; Jonsson M; Staaf J; Lewensohn R; Planck M
Conference publication: JOURNAL OF TRANSLATIONAL MEDICINE. 2020;18
Toward transcriptomics-based prediction of response to Immune Checkpoint Inhibitor in patients with malignant melanoma
Mallardo D; Alexeyenko A; Capone M; Madonna G; Ong S; Warren S; Viktorsson K; Franzen B; Tuffanelli M; Curvietto M; Vanella V; Festino L; Vitale M; Scognamiglio G; Beechem J; Botti G; Cesano A; Lewensohn R; Masucci GV; Ascierto PA
Conference publication: JOURNAL OF THORACIC ONCOLOGY. 2019;14(10):S814
Factors of Importance for Survival After Platinum Re-Challenge in Platinum-Sensitive Small-Cell Lung Cancer Patients
Tendler S; Zhan Y; Pettersson A; Lewensohn R; Viktorsson K; Fang F; De Petris L
Conference publication: JOURNAL OF THORACIC ONCOLOGY. 2019;14(10):S842
An Open-Label PET-MRI Study to Determine Brain Exposure of Osimertinib in Patients with EGFR Mutant NSCLC and CNS Metastases
Ekman S; Varrone A; Jucaite A; Vishwanathan K; Brown A; Cselenyi Z; Martin H; Lewensohn R; Schou M; Laus G; Van Der Aart J; Johnstrom P; Singh N; Farde L
Meeting abstract: JOURNAL OF THORACIC ONCOLOGY. 2019;14(10):s784
Analysis of Human Papilloma Viruses (HPV) and Human Polyoma Viruses (HPyV) in Lung Cancer from Swedish Never-Smokers
Ramqvist T; Ortiz-Villalon C; Branden E; Koyi H; De Petris L; Wagenius G; Brodin O; Reutersward C; Dalianis T; Jonsson M; Staaf J; Lewensohn R; Planck M
Meeting abstract: JOURNAL OF THORACIC ONCOLOGY. 2019;14(10):s568-s569
Lung Cancer in Never-Smokers: A Nationwide Population Based Mapping of Targetable Alterations
Salomonsson A; Jonsson M; Reutersward C; Behndig A; Bergman B; Botling J; Branden E; Brunnstrom H; De Petris L; Hussein A; Johansson M; Koyi H; Lundstrom KL; Lewensohn R; Monsef N; Ortiz-Villalon C; Patthey A; Vikstrom A; Wagenius G; Staaf J; Planck M
Conference publication: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2019;7
Real World data analysis related to metastatic melanoma patients treated with immunotherapy from 2012 to 2018 at Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale" of Napoli, Italy
Madonna G; Capone M; Tuffanelli M; Curvietto M; Paone M; Esposito A; Sorrentino A; Palla M; Scarpato L; Mallardo D; Simeone E; Grimaldi A; Viktorsson K; Villabona L; Lewensohn R; Masucci G; Ascierto PA
Published conference paper: RADIATION PROTECTION DOSIMETRY. 2018;182(1):80-84
COORDINATION OF MANAGEMENT OF THE ACUTE RADIATION SYNDROME
Stenke L; Lindberg K; Lindberg ML; Lewensohn R; Valentin J; Powles R; Dainiak N
Conference publication: JOURNAL OF THORACIC ONCOLOGY. 2018;13(10):S976
A Retrospective Study Examining the Role of PET-CT in the 8th TNM Staging System of SCLC
Tendler S; Grozman V; Lewensohn R; Tsakonas G; Viktorsson K; De Petris L
Corrigendum: LUNG CANCER. 2018;123:178-179
Validation of the 8th TNM classification for small-cell lung cancer in a retrospective material from Sweden (vol 120, pg 75, 2018)
Tendler S; Grozman V; Lewensohn R; Tsakonas G; Viktorsson K; De Petris L
Conference publication: EUROPEAN JOURNAL OF CANCER. 2018;103:E97
Extracellular vesicle analysis as non-invasive tool to predict and follow treatment response in bladder cancer
Haag P; Sha CH; Farnebo J; Hydbring P; Arapi V; Lewensohn R; Viktorsson K; Ullen A
Conference publication: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2017;99(2):E474
HILUS-Retrospective-A Retrospective Toxicity Analysis of Patients Treated with SBRT for Centrally Located Lung Lesions
Lindberg K; Karlsson K; Grozman V; Andersson A; Lax I; Ll PW; Lewensohn R
Meeting abstract: CANCER RESEARCH. 2017;77:5028
Whole exome sequencing and genetic association of gemcitabine/carboplatin induced thrombocytopenia in non-small cell lung cancer patients
Bjorn N; Svedberg A; Sigurgeirsson B; Pradhananga S; Branden E; Koyi H; Lewensohn R; De Petris L; Rodriguez-Antona C; Apellaniz-Ruiz M; Lundeberg J; Green H
Meeting abstract: CANCER RESEARCH. 2017;77:5026
Association to drug-induced leukopenia using whole-exome sequencing of non-small cell lung cancer patients on gemcitabine/carboplatin regimen
Svedberg A; Sigurgeirsson B; Bjorn N; Pradhananga S; Branden E; Koyi H; Lewensohn R; De Petris L; Rodriguez-Antona C; Apellaniz-Ruiz M; Lundeberg J; Green H
Conference publication: JOURNAL OF THORACIC ONCOLOGY. 2017;12(1):S340
The Nordic HILUS-Trial - First Report of a Phase II Trial of SBRT of Centrally Located Lung Tumors
Lindberg K; Bergstrom P; Brustugun OT; Engelholm S; Grozman V; Hoyer M; Karlsson K; Khalil A; Kristiansen C; Lax I; Loden B; Nyman J; Persson G; Rogg L; Wersall P; Lewensohn R
Conference publication: JOURNAL OF THORACIC ONCOLOGY. 2017;12(11):S2113
Clinical Significance of the Tumor Expression of PD-L1 Using Four Immunohistochemistry Assays in Non-Small Cell Lung Cancer. Multicentre Study
Ortiz-villalon C; Yoshikawa A; Kis L; Montero A; Roden A; Pham HHN; Fernandez C; Fukuoka J; Lewensohn R; De Petris L
Conference publication: JOURNAL OF THORACIC ONCOLOGY. 2017;12(1):S987
Profiling of Eph Signaling in Malignant Pleural Effusions- Identification of Therapy Approaches and Associated Biomarkers
Novak M; Haag P; Chomej KZ; Qian X; De Petris L; Ekman S; Hydbring P; Kamali C; Kanter L; Lofdahl M; Nilsson M; Viktorsson K; Lewensohn R
Conference publication: JOURNAL OF THORACIC ONCOLOGY. 2017;12(11):S1921-S1922
Exosomal RNA-Profiling of Lung Pleural Effusions Identifies Adenocarcinoma Patients through Elevated miR-200 Expression
Hydbring P; De Petris L; Branden E; Koyi H; Novak M; Kanter L; Haag P; Hurley J; Tadigotla V; Skog J; Viktorsson K; Ekman S; Lewensohn R
Meeting abstract: JOURNAL OF THORACIC ONCOLOGY. 2017;12(1):S1514
Clinical Significance of PD-L1 Status and the Expression of PD-1 in Tumor-Infiltrating Lymphocytes (TILs) in Lung Cancer
Ortiz-Villalon C; Karagkounis G; Kis L; Lewensohn R; Rassidakis G; Tendler S; De Petris L
Meeting abstract: JOURNAL OF THORACIC ONCOLOGY. 2017;12(1):S723-S724
Educational Level and Management in Small-Cell Lung Cancer (SCLC): A Population-Based Study
Tendler S; Holmqvist M; Wagenius G; Lewensohn R; Viktorsson K; De Petris L
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2016;34(15):e20096
Educational level and outcome in small-cell lung cancer (SCLC): A population-based study.
Tendler S; Holmqvist M; Wagenius G; Lewensohn R; Viktorsson K; Lambe M; De Petris L
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2016;34(15):e20031
Clinical significance of the tumor expression of PD-L1 in lung cancer.
De Petris L; Ortiz-Villalon C; Kis L; Tendler S; Friesland S; Lewensohn R
Conference publication: JOURNAL OF THORACIC ONCOLOGY. 2016;11(4):S96
Validation of the 7th and upcoming 8th TNM staging system in small cell lung cancer
Tendler S; Lewensohn R; Viktorsson K; de Petris L
Conference publication: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2015;93(3):E481-E482
SBRT of Large Tumors: A Retrospective Study
Grozman V; Wersall P; Lax I; Lewensohn R
Conference publication: RADIOTHERAPY AND ONCOLOGY. 2015;115:S324-S325
Radiation induced brachial plexus toxicity after SBRT of apically located lung lesions
Lindberg K; Grozman V; Lindberg S; Lax I; Lewensohn R; Wersall P
Book chapter: DEVELOPMENTS IN T CELL BASED CANCER IMMUNOTHERAPIES: CANCER DRUG DISCOVERY AND DEVELOPMENT. 2015;p. 211-229
T Cell Blockade Immunotherapy Against Cancer and Abscopal Effect in Combination Therapy
Masucci GV; De Petris L; Lundqvist A; Kiessling R; Lewensohn R
Meeting abstract: EUROPEAN JOURNAL OF CANCER. 2014;50:184
Modulation of chromatin-related processes in DNA damage response as a potential strategy to treat acute myeloid leukemia
Chomej K; Lindberg ML; Zong D; Juntti T; Kanter L; Stenke L; Lewensohn R; Viktorsson K; Haag P
Meeting abstract: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2014;90:S780
Alternating Electric Fields (TTFields) Inhibit Repair of DNA Damage Induced by Ionizing Radiation and Sensitize Glioma and Non-Small Cell Lung Cancer Cells to Radiation
Zielinska-Chomej K; Giladi M; Tichon A; Tu J; Schneiderman R; Viktorsson K; Kirson E; Palti Y; Lewensohn R
Conference publication: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2014;90:S326
Outcome After SBRT of Adrenal Gland Metastases: A Multicenter Retrospective Analysis of 60 Adrenal Metastases
Lindberg K; Grozman V; Haasbeek C; Westman G; Lax I; Wersall P; Andersson A; Lewensohn R
Review: CELL DEATH AND DISEASE. 2014;5(5):e1260
Systems biology approaches to develop innovative strategies for lung cancer therapy
Viktorsson K; Lewensohn R; Zhivotovsky B
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2014;32(15):e22239
The effect of alternating electric fields (TTFields) on inhibition of repair of DNA damage induced by ionizing radiation and sensitization of glioma and non-small cell lung cancer cells to radiation.
Giladi M; Zielinska-Chomej K; Tichon A; Tu J; Schneiderman RS; Vlktorsson K; Kirson ED; Palti Y; Lewensohn RM
Conference publication: RADIOTHERAPY AND ONCOLOGY. 2014;111:S221
SPACE - A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC
Nyman J; Hallqvist A; Lund JA; Brustugun OT; Bergstrom P; Friesland S; Lewensohn R; Drugge N; Rylander H; Lax I
Conference publication: MOLECULAR CANCER THERAPEUTICS. 2013;12(11):a170
Analysis of marine sponge Cribrochalina vasculum compounds demonstrate selective antitumor properties by activation of intrinsic apoptotic signaling and impaired growth factor receptor signaling cascades.
Zovko A; Viktorsson K; Haag P; Ilan M; Kovalerchick D; Carmeli S; Alimonti A; Lewensohn R
Meeting abstract: MOLECULAR CANCER THERAPEUTICS. 2013;12(11):b19
Phenothiazines induce cytotoxicity and enhance chemotherapy-induced cell death signaling in acute myeloid leukemia.
Haag P; Zielinska-Chomej K; Juntti T; Kanter L; Lewensohn R; Stenke L; Viktorsson K
Editorial comment: JOURNAL OF TRANSLATIONAL MEDICINE. 2012;10:104
Stereotactic Ablative Radio Therapy (SABR) followed by immunotherapy a challenge for individualized treatment of metastatic solid tumours
Masucci GV; Wersall P; Kiessling R; Lundqvist A; Lewensohn R
Conference publication: CANCER RESEARCH. 2011;71:p1-06-19-p1-06-19
Absence or Low Levels of c-JunNH2 Terminal Protein Kinase (JNK) Mitogen Activated Protein Kinase (MAPK) Is Related to a Luminal B Subtype and an Impaired Survival in Patients with an ER Positive Breast Cancer Treated with Adjuvant Tamoxifen.
Linderholm BK; Sanchez-Chavez B; Hellborg H; Johansson UM; Lewensohn R; Viktorsson K; Kanter L
Meeting abstract: EUROPEAN JOURNAL OF CANCER. 2011;47:S124
Plasma Metabolomics in Non-small-cell Lung Cancer
De Petris L; Forshed J; Antti H; Branden E; Koyi H; Johnsson A; Lewensohn R; Lehtio J
Conference publication: CANCER RESEARCH. 2011;71:4090
The role of caspase-2 in apoptotic signaling in AML cells
Haag P; Lindberg ML; Kanter L; Stenke L; Lewensohn R; Viktorsson K
Conference publication: CANCER RESEARCH. 2011;71:163
mRNA and miRNA profiling of platinum-resistant non-small cell lung cancer cell clones identifies potential targets involved in DNA metabolism and DNA replication
Salim HM; Lundholm L; Zong D; Haag P; Mork B; Viktorsson K; Lewensohn R
Conference publication: CANCER RESEARCH. 2011;71:2541
Inhibition of DNA repair by trifluoperazine sensitizes human lung cancer cells to apoptosis associated with lysosomal dysfunction following prolonged G2-M checkpoint arrest
Zong D; Haag P; Lewensohn R; Viktorsson K
Meeting abstract: EJC SUPPLEMENTS. 2010;8(7):69
The alkylating prodrug J1 inhibits ovarian cancer cell growth, activates proapoptotic signalling and potentiates gemcitabine responsiveness in vitro and in vivo in mice
Viktorsson K; Gullbo J; Juntti T; Wickstrom M; Larsson R; Lewensohn R; Spira J
Meeting abstract: EJC SUPPLEMENTS. 2010;8(5):134
Global gene analysis reveals ephrin B3 as a potential radio sensitizing target in non small cell lung cancer cells
Stahl S; Vaculova A; Kaminskyy V; Rodriguez-Nieto S; Moshfegh A; Lewensohn R; Viktorsson K; Zhivotovsky B
Meeting abstract: EJC SUPPLEMENTS. 2010;8(5):134-135
The DNA glycosylase Myh1 is stabilized by cisplatin and inhibition of Myh1 expression increases cisplatin-induced apoptotic signaling in lung carcinoma cells
Viktorsson K; Efazat G; Haag P; Zong D; Stenke L; Sunnerhagen P; Lewensohn R
Meeting abstract: EJC SUPPLEMENTS. 2010;8(5):113
miRNA and cancer stem cell analysis of NSCLC to explain the sensitizing effect of trifluoperazine on cisplatin-induced cell death signaling
Lundholm L; Zong D; Haag P; Salim H; Lewensohn R; Viktorsson K
Meeting abstract: EJC SUPPLEMENTS. 2010;8(5):57
Cytotoxicity and cell death signaling in stem cell like AML cells
Haag P; Lindberg ML; Zong D; Kanter L; Lewensohn R; Stenke L; Viktorsson K
Review: JOURNAL OF NEUROIMMUNE PHARMACOLOGY. 2010;5(1):4-17
Metabolomics: Moving to the Clinic
Nordstrom A; Lewensohn R
Review: PROTEOMICS. 2009;9(6):1420-1427
Affinity prefractionation for MS-based plasma proteomics
Pernemalm M; Lewensohn R; Lehtio J
Conference publication: LUNG CANCER. 2009;64:S13
WILL STEREOTACTIC BODY RADIOTHERAPY PROLONG SURVIVAL IN PATIENTS WITH STAGE IV NSCLC?
Baumann R; Lewensohn R
Conference publication: RADIOTHERAPY AND ONCOLOGY. 2008;88:S171-S172
STEREOTACTIC BODY RADIOTHERAPY FOR MEDICALLY INOPERABLE PATIENTS WITH STAGE I NON-SMALL CELL LUNG CANCER. AN EARLY REPORT FROM A PROSPECTIVE PHASE II STUDY.
Baumann P; Nyman J; Hoyer M; Gagliardi G; Lax I; Wennberg B; Drugge N; Ekberg L; Friesland S; Johansson KA; Lund JA; Morhed E; Nilsson K; Levin N; Paludan M; Sederholm C; Traberg A; Wittgren L; Lewensohn R
Review: TUMOR BIOLOGY. 2008;29(5):311-322
Current Status of Prognostic Immunohistochemical Markers for Urothelial Bladder Cancer
Rosenblatt R; Jonmarker S; Lewensohn R; Egevad L; Sherif A; Kalkner KM; Nilsson S; Valdman A; Ullen A
Meeting abstract: JOURNAL OF THORACIC ONCOLOGY. 2007;2(8):S356-S357
Mass spectrometry profiling of low molecular weight platelet Proteome for the detection of lung cancer specific biomarkers
De Petris L; Pernemalm M; Branden E; Koyi H; Forshed J; Sundelin B; Lewensohn R; Lehtio J
Editorial comment: JOURNAL OF THORACIC ONCOLOGY. 2007;2(3):175-179
Apoptotic signaling pathways in lung cancer
Viktorsson K; Lewensohn RF
Published conference paper: ACTA ONCOLOGICA. 2006;45(7):973-977
Dummy run for a phase II study of stereotactic body radiotherapy of T1-T2 N0M0 medical inoperable non-small cell lung cancer
Djarv E; Nyman J; Baumann P; Ekberg L; Hoyer M; Lax I; Lewensohn R; Levin N; Lund J-A; Morhed E; Ericsson SR; Traberg A; Wittgren L; Johansson K-A
Published conference paper: ACTA ONCOLOGICA. 2006;45(7):787-795
Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries
Baumann P; Nyman J; Lax I; Friesland S; Hoyer M; Ericsson SR; Johansson K-A; Ekberg L; Morhed E; Paludan M; Wittgren L; Blomgren H; Lewensohn R
Corrigendum: EXPERIMENTAL AND MOLECULAR PATHOLOGY. 2005;79(1):86
Expression of DNA-PKcs and Ku86, but not Ku70, differs between lymphoid malignancies (vol 77, pg 1, 2004)
Holgersson Å; Erdal H; Nilsson A; Lewensohn R; Kanter L
Review: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2005;331(3):868-880
The role of p53 in treatment responses of lung cancer
Viktorsson K; De Petris L; Lewensohn R
Review: ADVANCES IN CANCER RESEARCH. 2005;94:143-196
Apoptotic pathways and therapy resistance in human malignancies
Viktorsson K; Lewensohn R; Zhivotovsky B
Review: LUNG CANCER. 2003;41(1):1-11
The role of radiotherapy in treatment of stage I non-small cell lung cancer
Qiao XY; Tullgren O; Lax I; Sirzén F; Lewensohn R
Corrigendum: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2001;284(4):1091
DNA-dependent protein kinase is inhibited by trifluoperazine (vol 283, pg 726, 2001)
Eriksson Å; Yachnin J; Lewensohn R; Nilsson A
Review: LAKARTIDNINGEN. 2000;97(3):164-167
[Radioimmunotherapy is rapidly developing to clinically efficient therapy].
Stenke L; Lewensohn R; Carlsson J
Published conference paper: ANNALS OF THE NEW YORK ACADEMY OF SCIENCES. 2000;926:204-216
Role of apoptosis in the response of lung carcinomas to anti-cancer treatment
Joseph B; Lewensohn R; Zhivotovsky B
Published conference paper: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 1997;39(2):303-308
Hypothyroidism after external radiotherapy for head and neck cancer
Tell R; Sjodin H; Lundell G; Lewin F; Lewensohn R
Conference publication: PIGMENT CELL AND MELANOMA RESEARCH. 1988;1(4):288
A TRIPEPTIDE CONTAINING M-L-SARCOLYSIN IS MORE TOXIC TO HUMAN-MELANOMA CELLS COMPARED TO M-L-SARCOLYSIN ALONE
RINGBORG U; LEWENSOHN R; HANSSON J
Conference publication: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 1986;87(3):432
THE INCORPORATION OF THYMIDINE-H-3 (T) AND H-3 URIDINE (U) IS DIFFERENTIALLY INHIBITED BY MELPHALAN IN MELANOMA AND LYMPHOBLAST CELLS AT SIMILAR LEVELS OF DNA CROSS-LINKING
RINGBORG U; HANSSON J; LEWENSOHN R
Conference publication: PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. 1986;27:235
MELPHALAN AND NITROGEN-MUSTARD INDUCED TOXICITY AND DNA CROSS-LINKING IN HUMAN-MELANOMA CELLS
HANSSON J; LEWENSOHN R; RINGBORG U
Conference publication: PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. 1984;25(MAR):336
DNA CROSSLINKING AND TOXICITY IN HUMAN-MELANOMA AND LYMPHOBLAST CELLS TREATED WITH MELPHALAN, META-L-SARCOLYSIN AND PEPTICHEMIO
LEWENSOHN R; HANSSON J; RINGBORG U
Book chapter: CANCER CHEMOTHERAPY AND SELECTIVE DRUG DEVELOPMENT: DEVELOPMENTS IN ONCOLOGY. 1984;p. 539
CIS-Diamminedichloroplatinum Toxicity and DNA Crosslinking in Human Melanoma and Lymphoblast Cells
Hansson J; Ringborg U; Lewensohn R
Visa fler

Forskningsbidrag

Lewensohn, Rolf Marcel - Development of new curative treatment for lung cancer using precision radiotherapy alone and combined with targeted drugs or immunotherapy.
Swedish Cancer Society
1 January 2022
Prognosticating cancer outcome with image analysis and machine learning
Swedish Research Council
1 January 2019 - 31 December 2022
Development of new curative treatment for lung cancer using precision radiation therapy alone and combined with targeting drugs or immunotherapy.
Swedish Cancer Society
1 January 2018
Molecular and clinical studies of lung cancer with the goal of creating improved and individualized treatment.
Swedish Cancer Society
1 January 2017
Minimally invasive bio marker-based cancer diagnostics and treatment prediction
VINNOVA
11 April 2016 - 19 January 2017
Molecular and clinical studies of lung cancer with the goal of creating improved and individualized treatment.
Swedish Cancer Society
1 January 2016
National Workshop on ”Personalized Cancer Medicine” (PCM)
Swedish Foundation for Strategic Research
10 August 2015 - 30 June 2016
Molecular and clinical studies of lung cancer with the goal of creating improved and individualized treatment.
Swedish Cancer Society
1 January 2015
Molecular and clinical studies of lung cancer with the goal of creating improved and individualized treatment.
Swedish Cancer Society
1 January 2014
Discovery of novel radiotherapeutic strategies for cancer treatement using a systems biology approach
Swedish Research Council
1 January 2010 - 31 December 2012

Anställningar

Professor, Senior, Onkologi-Patologi, Karolinska Institutet, 2025-2025
Professor, Onkologi-Patologi, Karolinska Institutet, 2020-2024

Examina och utbildning

Docent, Onkologi, Karolinska Institutet, 1982

Nyheter från KI

Kalenderhändelser från KI